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Abstract
Identifying Prognostic Gene Signatures Using a Network-Based Approach
Swetha Bose Nutakki
The main objective of this study is to develop a novel network-based methodology to identify
prognostic signatures of genes that can predict recurrence in cancer. Feature selection algorithms were
used widely for the identification of gene signatures in genome-wide association studies. But most of
them do not discover the causal relationships between the features and need to compromise between
accuracy and complexity. The network-based techniques take the molecular interactions between pairs of
genes in to account and are thus a more efficient means of finding gene signatures, and they are also
better in terms of its classification accuracy without compromising over complexity. Nevertheless, the
network-based techniques currently being used have a few limitations each. Correlation-based
coexpression networks do not provide predictive structure or causal relations among the genes. Bayesian
networks cannot model feedback loops. Boolean networks can model small scale molecular networks, but
not at the genome-scale. Thus the prediction logic induced implication networks are chosen to generate
genome-wide coexpression networks, as they integrate formal logic and statistics and also overcome the
limitations of other network-based techniques.
The first part of the study includes building of an implication network and identification of a set
of genes that could form a prognostic signature. The data used consisted of 442 samples taken from 4
different sources. The data was split into training set UM/HLM (n=256) and two testing sets DFCI (n=82)
and MSK (n=104). The training set was used for the generation of the implication network and eventually
the identification of the prognostic signature. The test sets were used for validating the obtained signature.
The implication networks were built by using the gene expression data associated with two disease states
(metastasis or non-metastasis), defined by the period and status of post-operative survival. The gene
interactions that differentiated the two disease states, the differential components, were identified. The
major cancer hallmarks (E2F, EGF, EGFR, KRAS, MET, RB1, and TP53) were considered, and the
genes that interacted with all the major hallmarks were identified from the differential components to
form a 31-gene prognostic signature. A software package was created in R to automate this process which
has C-code embedded into it. Next, the signature was fitted into a COX proportional hazard model and
the nearest point to the perfect classification in the ROC curve was identified as the best scheme for
patient stratification on the training set (log-rank p-value =1.97e-08), and two test sets DFCI (log-rank pvalue =2.13e-05) and MSK (log-rank p-value = 1.24e-04) in Kaplan-Meier analyses.
Prognostic validation was carried out on the test sets using methods such as Concordance
Probability Estimate (CPE) and Gene Set Enrichment Analysis (GSEA). The accuracy of this signature
was evaluated with CPE, which achieves 0.71 on the test set DFCI (log-rank p-value= 5.3e-08) and 0.70
on test set MSK (log-rank p-value =2.1e-07). The hazard ratio of this 31-gene prognostic signature is 2.68
(95% CI: [1.88, 3.82]) on the DFCI dataset and 3.31 (95% CI: [2.11, 5.2]) on the MSK set. These results
demonstrate that our 31-gene signature was significantly more accurate than previously published
signatures on the same datasets. The false discovery rate (FDR) of this 31-gene signature is 0.21 as
computed with GSEA, which showed that our 31 gene signature was comparable to other lung cancer
prognostic signatures on the same datasets.
Topological validation was performed on the test sets for the identified signature to validate the
computationally derived molecular interactions. The interactions from implication networks were
compared with those from Bayesian networks implemented in Tetrad IV. Various curated databases and
bioinformatics tools were used in the topological evaluation, including PRODISTIN, KEGG, PubMed,
NCI-Nature pathways, MATISSE, STRING 8, Ingenuity Pathway Analysis, and Pathway Studio 6. The
results showed that the implication networks generated all the curated interactions from various tools and
databases, whereas Bayesian networks contained only a few of them. It can thus be concluded that
implication networks are capable of generating many more gene or protein interactions when compared to
the currently used network techniques such as Bayesian networks.
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Chapter 1

1 Introduction
Lung Cancer is caused due to the uncontrolled growth of cells in the tissues of lungs. It is critical
to identify gene signatures that can predict cancer recurrence to improve patient care. Genes
having high degree of connections with the major cancer markers have strong impact on the
network topology [7] and are thus the critical genes of the network. There are different
techniques which can identify these critical genes.
Feature selection techniques have been used earlier to find prognostic markers from a group of
data by eliminating genes which have little or almost no predictive information [47]. These
techniques were used in machine learning particularly for the purpose of removing irrelevant or
redundant features from data and forming a subset of relevant features. Though feature selection
techniques have a good number of advantages, they still have a few limitations. When there are a
large number of features, the search for a good subset of features (which provides optimal
results) becomes very complicated and tedious. Moreover feature selection techniques consider
the behavior of genes individually which might not act in the same manner in the presence or
absence of other genes.
Network-based techniques can be used to find gene signatures and overcome the limitations of
feature selection methods. Network-based techniques work in uncovering the causal
relationships between the genes and are also better in terms of stability and classification
accuracy [7] and thus they are an efficient means of finding prognostic gene signatures when
compared to feature selection algorithms. They consider the signature of genes as a whole
instead of considering each gene individually and thus emphasize on the molecular interactions
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between pairs of genes. This works well as genes might not act in the same way when they are
alone and when they are acting along with other regulators. Network-based techniques are more
useful in cases where huge datasets come into picture [8]. This is due to the fact that performing
an exhaustive or complete feature selection technique on a huge dataset would be very time
taking and also requires a lot of resources. Most of the lung cancer datasets are huge and thus
using these network techniques helps in identifying signatures faster and in an accurate manner
and it also helps in analyzing the signatures in a better way.
Currently, there are different network-based techniques that are in use such as coexpression
network, Bayesian network, and artificial neural network. Though these network-based
techniques overcome the limitations of feature selection methods, they still have a few
limitations each. Correlation-based coexpression networks are inconsistent as their accuracy
decreases with increase in network size [7]. Bayesian networks cannot model feedback loops and
their complexity increases exponentially with the number of genes in the network [4]. Artificial
neural networks are very complex and time taking in nature. Moreover to our knowledge, neural
networks have not been used for modeling molecular interactions yet.
To overcome the limitations of the currently used network-based techniques, implication
networks based on prediction logic were chosen to generate the genome wide networks [2]. The
methodology used in implication networks is computationally manageable for analyzing large
datasets and integrates formal logic and statistics [1], thus making it more efficient.
To generate the genome wide networks based on prediction logic [2], the gene expression data
(from University of Michigan Cancer Center (UM) and Moffitt Cancer Center (HLM) together used as
training dataset [20]) was separated in to two groups (metastasis: corresponds to the high risk
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group and non-metastasis: corresponds to the low risk group) based on the survival period and
survival status. The genome wide networks of both the groups were compared and the common
interactions they have were removed. Thus we could focus on the differential components in
networks that remained which are the interactions that differentiated the metastasis group from
the non-metastasis group.
To identify prognostic signatures, major cancer hallmarks such as E2F, EGF, EGFR, KRAS, MET,
RB1, and TP53 were considered and the genes that interact with all these major cancer hallmarks

were considered to form a signature. The hallmark E2F had many probes like E2F1, E2F2, E2F3,
E2F4, and E2F5. These probes can be picked in various combinations depending on their
functionality. Thus different sets of hallmarks can be considered. Different signatures can be
identified by varying the set of hallmarks used to pick the genes. Thus different gene signatures
were identified based on the interactions between the genes and the hallmarks under diseased
conditions.
To identify the most prognostic signature from the obtained signatures, survival analysis [35]
was done using techniques such as Time-dependent ROC [16] (statistical p-values and area
under curves (AUC) over time were used as measures to compare the different signatures),
Random testing (different signatures as the same size of the identified signatures were picked
randomly and checked where our signature stands among the randomly picked signatures), and
COX proportional hazard model [18, 19, 28] (Kaplan-Meier plots and log-rank test results were
observed). For analysis with COX proportional hazard model, both univariate (considering the
gene expression values of the genes only) and multivariate analysis (considering the risk scores
of the signatures as a predictor and comparing with other predictors such as age, gender,
smoking status, tumor size etc. with and without the risk scores) were done. Kaplan Meier plots
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were used for determining the significance of the signature in differentiating the two groups from
one another. Log-rank p-values were observed from the COX proportional hazard model and
signature was picked which had values less than 0.05 for training and test sets, showing it to be
significant. Multivariate analysis using the COX proportional hazard model was done as a part of
the evaluation of the signature with respect to other clinical parameters.
To validate the signature obtained, both prognostic and topological validation was performed on
the test datasets (from Memorial Sloan-Kettering Cancer Center (MSK) and the Dana-Farber Cancer
Institute (CAN/DF) [20]). The prognostic validation was conducted using techniques such as

Overall Accuracy [32], Concordance Probability Estimate (CPE) [29], and Gene Set Enrichment
Analysis (GSEA) [30]. Sensitivity and specificity were measured along with the overall accuracy
values. CPE was used to evaluate the distinguishing power and the predictive accuracy of the
statistical model. CPE measures included the statistical log-rank p-values, hazard ratios, and 95%
confidence intervals which were compared with published signature from Shedden et al [20].
The results showed that the 31-gene signature had more significant statistical p-values, higher
hazard ratios, and higher CPE values which confirm that the signature is better when compared
to the other published signature. GSEA is a powerful analytical method that computed whether
the 31 gene signature is statistically significant and whether the gene set has agreeable
differences between the two phenotypes (biological states). GSEA was used to compare our
signature with many other previous signatures using False Discovery Rates (FDR) and
Normalized Enrichment Scores (NES). GSEA results showed that the signature had FDR < 0.25
which makes it significant. The comparisons above showed that our signature was either
comparable or better than the other signatures on the same datasets.
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To topologically validate the gene signature, the interactions from implication network were
compared with interactions from Bayesian network generated by Tetrad IV1. Then various tools
such as Prodistin2, KEGG3, NCI4 pathways, PubMed5, Matisse6, String7, Ingenuity Pathway
Analysis8, and Pathway studio9 were used. These tools extracted their interactions from various
sources such as literature, curated databases, etc. All the interactions found from the above
mentioned tools were compared with the interactions generated from implication network and
interactions from Tetrad IV (Bayesian network).
From the interactions extracted from various biomedical tools, it was concluded that implication
networks are capable of generating many more gene or protein interactions which were validated
by the molecular interactions from other tools when compared to the Bayesian networks. The
functional classes identified from the signature reveal that the genes are not just structurally
connected but also have biological relationships. Thus these genes could be focused in predicting
cancer recurrence in therapeutic conditions.
The chapters in this thesis are as divided as follows. The second chapter provides literature
review of the currently used techniques. It also provides descriptions of all the methods and webbased tools used in this study. The third chapter describes the methodology used to identify the
gene signature from the genome wide coexpression networks. The fourth chapter discusses the
results obtained from prognostic and topological validation techniques. The fifth chapter
describes the implementation of the software used to generate the results in both C and R10. It
1. http://www.phil.cmu.edu/projects/tetrad/
2. http://crfb.univ-mrs.fr/webdistin/
3. http://www.genome.jp/kegg/
4. http://pid.nci.nih.gov/
5. http://www.ncbi.nlm.nih.gov/pubmed/
6. http://acgt.cs.tau.ac.il/matisse/
7. http://string.embl.de/
8. http://www.ingenuity.com/
9. http://www.ariadnegenomics.com/products/pathway-studio/
10. http://www.r-project.org
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also describes the versions of the editors and the configuration of the system used to run the
analyses. The sixth chapter concludes all the above mentioned chapters and also includes the
prospective work that will be carried out relating this approach.
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Chapter 2

2 Background
2.1

Introduction

This chapter describes various techniques to identify signatures. Feature selection methods are
described in brief followed by their limitations. These limitations are overcome by introduced
network-based techniques. Different network-based techniques currently used such as
correlation-based coexpression networks, Bayesian belief networks, and artificial neural
networks are discussed followed by their limitations which are overcome by the implication
networks. The implication networks are discussed and the algorithm which has been used to
induce the implication networks is discussed. Different validation techniques which have been
used to validate the signature found from implication networks were discussed. Finally a
summary of the entire chapter is given.

2.2

Different techniques to identify signatures

There are different procedures to identify gene signatures. Potential markers have been screened
earlier by identifying the overexpressed or the underexpressed genes. But this process is not
good enough as the information of each individual gene is considered when the interactions
between genes were supposed to be considered [15].
Feature selection [47] techniques have been used earlier to find prognostic markers from a group
of data by eliminating genes which have little or almost no predictive information. These
techniques were used in machine learning particularly for the purpose of removing irrelevant or
redundant features from data and forming a subset of relevant features. They help in overcoming
7

the curse of dimensionality by reducing the number of features that have to be considered and
thus speeding up the process. They can be used with both supervised (to produce high
classification accuracy) and unsupervised learning (to find good subsets of features that form
quality clusters). Though feature selection techniques have several advantages such as removal
of redundant and irrelevant features, improving the classifier performance, etc., they still have a
few limitations. When there are a large number of features in the beginning, as in the case of
lung cancer genes, feature selection techniques become very complicated and it becomes tedious
to find a good subset of features. Moreover they consider the genes individually which might not
act in the same manner in the presence or absence of other genes.
The most important advantage of network-based approaches over feature selection methods is
that they can capture and represent more complex types of relationships among genes or any
variables of interest [8]. Since there will be a large number of relationships between genes,
methods other than network-based procedures become more complex and the computation of
such models becomes very tedious (for example, in case of feature selection methods, optimal
output requires exhaustive search which is very time consuming). Network-based techniques
help in revealing the underlying molecular mechanisms related to the genes. Networks built with
genes can be used to identify disease mechanisms [34] and for drug discovery [33], and also for
identifying prognostic subnetworks which lead to metabolic pathways [33]. Other methods (such
as feature selection techniques) ignore genes which do not have significant differential
expression individually in different classes but which actually play vital roles as a member of a
group in certain pathways.
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Gene networks are constructed in such a way that any pair of genes are connected if some
measure (calculated from the current conditions of the genes) related to both the genes exceeds a
given threshold [13].
There are many network-based approaches that are already in use for classification analyses and
for identifying interactions between genes. Some of them are described below.
2.2.1 Coexpression Network
Gene coexpression network connects genes with similar expression profiles (such as the Pearson
correlation coefficient [15] or the clustering coefficient [13]) and thus connects functionally
related genes [13, 15]. This network tries to investigate the transcriptional changes in terms of
“gene interactions” rather than at the level of “individual genes”.
Pearson correlation coefficient measures the degree of linear dependence between two timecourses of gene expression levels [14]. It is close to one when there is good correlation between
the time series. It is near negative one when there is negative correlation and is close to zero
when there is no correlation between the expression values [42]. It can be calculated as shown
below. If

stands for correlation between the genes

expression values of genes

and

respectively;

standard deviations of the genes

and

and

respectively;

and

;

and

are the means and

are the gene
and

are the

is the total number of genes; then

Pearson correlation ( ) is defined as

,

1

(2.1)
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Hence Pearson correlation ( ) was calculated for each dataset and was converted in to a standard
normal metric using the Fisher’s transformation [15]. This standard normal metric shown below
is called effect size ( ) which was used as a measure of treatment or covariate effect.
1
1

0.5

(2.2)

Clustering is generally used to cluster (group) genes based on a correlation-based distance
measure quantifying the degree of co-regulation [14]. Thus the function of an unknown gene can
be predicted from the known functions of other genes present in the same cluster [14]. Clustering
algorithms work well when the genes are co-regulated. Gene expression clusters can also be
mapped on to metabolic networks in order to discover pathways of interest. The clustering
coefficient of gene

is denoted by

first neighbors of gene and

and is calculated as shown below. If

is the number of edges between the

is the number of

first neighbors, clustering

coefficient of the entire network can be calculated by taking the average of the clustering
coefficients of all the genes in the network as shown below.
2
1

(2.3)

The underlying postulation of the network distance metric is that the enzymes are related
according to their proximity in the network. If this metric is above a specific threshold, the pair
of genes would be connected. It considers that a rise or fall in the correlation of a gene pair might
be associated with the upregulation or downregulation of other genes in the same functional
cluster. These networks constructed from pair-wise correlation coefficients have provided a
productive procedure to recognize functional transcriptional modules related with specific
biological processes [6].
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Aoki et al. [6] explored the gene co-expression networks in plant biology and concluded that coexpression network analysis provided innovative awareness in the system level understanding of
plant biology. In many cases, gene co-expression networks implied the presence of functional
linkage between genes associated with biological processes.
L.L. Elo et al [13] proposed a systematic approach for the estimation of the threshold of
coexpression networks directly from their topological properties. They used the clustering
coefficient for the threshold selection which when gradually increased reduced the number of
links from the initially complete graph of coexpression networks. They experimented on the
simulated data generated using the stochastic model of Thalamuthu et al [49] which consisted of
60 datasets. The biological relevance of the coexpression was investigated by the p-values.
Hanisch et al. [14] proposed the construction of a distance function (correlation-based distance
function) which combined the information from biological networks (in an integrated manner)
and gene expression data. They focused on the analysis of co-regulated metabolic pathways
which were supported by gene expression measurements. They calculated the Pearson
correlation coefficient on log-ratio transformed data and then converted it in to a distance metric
which quantified the degree of dissimilarity of their gene expression dataset. They defined a
graph distance function on the networks and combined it with correlation based distance function
for gene expression measurements. They conducted the experiments on the organism
S.cerevisiae (yeast).
Choi et al [15] introduced a model (mentioned above using Pearson correlation coefficient and
its Fisher transformation to find effect size) for finding the differential coexpression from
microarrays and testing its biological validity with respect to cancer. They collected data from 10
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published gene expression datasets from cancers of 13 various tissues and built 2 different
coexpression networks, a tumor network and a normal network which were compared.
S. Tornow and H. Mewes [41] proposed a technique which was based on collective, multi-body
correlations in a genetic network. They calculated the correlation strength of a group of genes in
a coexpression network which were identified as members of a module in another protein
interaction network and estimated its correlation probability.
Zhang and Horvath [43] proposed a general framework for soft thresholding which assigned a
connection weight to each gene pair. They used several adjacency functions (such as sigmoid
function, power adjacency function, etc.) to convert the correlation coefficients to connection
weights. They experimented on simulated data, a cancer microarray dataset and a yeast
microarray dataset.
Thus coexpression networks have been used in several applications such as for discovery of
genetic modules, applying to human T helper cell differentiation process [13], for topology based
cancer classification [7], for molecular characterization of cellular state, etc.
There are a few limitations of coexpression networks. Correlation-based coexpression networks
are based on similarities and clustering based coexpression networks are based on the distance
measures. Thus they do not provide a predictive structure and do not infer causal relationships
among genes. High correlation is exhibited by genes when the entire set of expression patterns
across different conditions is similar. On the other hand, high correlation is also exhibited by
genes if they are expressed together under a few conditions and are otherwise silent [6].
Moreover the accuracy of correlation-based coexpression networks decreases, as the network
size increases and it is highly inconsistent.
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2.2.2 Bayesian Network
The Bayesian networks model is a causal network which represents the joint probability
distributions. Bayesian networks are useful for describing complex probabilistic models which
require learning from noisy observations. Bayesian Networks are thus capable of estimating the
confidence in different features of the network and thus are a promising tool for examining gene
expression patterns [4].
,…,

If we have a finite set of random variables,
take values from the domain Val(

,

(whose vertices correspond to the random variables,
(given its parents in

is a variable which might

, Bayesian networks are represented using joint probability

distributions consisting of two components,

variable

, where

; a directed acyclic graph [4] (DAG)
) and a conditional distribution for each

). According to Markov assumption, each variable

independent of its non-descendents, given its parents in

is

and their joint probability distribution

can be defined as below [4].

,…,

Here

is the set of parents of

(2.4)

in

. Once networks are built, they are needed to be

scored by some means so that the networks are evaluated and the optimal network can be found.
Posterior probability can be used to evaluate the graphs. If a large number of networks are given,
learning procedures can pinpoint the exact network structure which has best dependencies in the
distribution.
Bayesian Networks were used to describe the interactions between genes in a paper by Friedman
et al. [4] where they described a method to recover the gene interactions from microarray data.
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They also applied the method to the S.cerevisiae cell-cycle measurements of Spellman et al.
(1998). They used priors described by Heckerman and Geiger (1995) for hybrid networks of
multinomial distributions and conditional Gaussian distributions.
It has been described by Friedman et al. [4] that a causal network models the distribution of the
observations as well as the effects of interventions.

and

networks but they are not equivalent in causal networks. If
of

are equivalent in Bayesian
causes , then changing the value

affects the value of . But it is not true the other side, i.e., changing the value of

affect the value of

does not

. Their approach was to analyze a high number of high scoring networks

which requires an efficient learning algorithm such as the Sparse Candidate algorithm. To relate
their analysis with the biological phenomena in the data, they used the order relations and
Markov relations found from their data.
As Bayesian networks have the capability of working even in highly noisy surroundings, it has
many real-world applications. Some of them in bioinformatics are for building gene regulatory
networks and protein structures [34]. They are also applicable to other fields such as medicine,
image processing, information retrieval, etc.
There are a few limitations to the Bayesian network approach. Since the Bayesian networks are
directed acyclic graphs, the probabilities of the child nodes are calculated from the parent nodes.
Thus Bayesian networks cannot have loops and they also require a subjective prior (for the first
parent node). Bayesian networks need complete knowledge of the real-world in order to build the
correct causal model. These networks are expensive to compute and the rate of complexity
increases exponentially with the number of genes present in the network [8]. Thus they become
more impractical and inappropriate.
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TETRAD IV11 and its search algorithms were developed with the support of National
Aeronautics and Space Administration and the Office of Naval Research. TETRAD IV is a
program for working on causal/statistical models particularly Bayesian belief networks. It is used
for creating, simulating data from, estimating, testing, predicting with and searching for causal
models. It has a friendly interface and no programming knowledge is required to use it. It is
unique in the suite of principled search algorithms.
A program description of a causal model is done in three stages in TETRAD IV. The first one is
a picture which uses a directed graph to state in detail the hypothetical causal relations among
variables. The second stage would be to specify the family of probability distributions and the
kinds of parameters associated with the graphical model. The final stage would be to specify the
numerical values of the parameters explained earlier.
Sessions in TETRAD IV are built by dragging boxes in to the workspace and then connecting
them with arrows in legal ways that represent their dependencies. The Figure 2-1 below shows
the model used in TETRAD IV to build Bayesian networks. This network was compared to the
implication network built using prediction logic.
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Figure 2-1: Model used in TETRAD IV showing all the boxes

Data box:
We use data that was loaded from an external file. Here “Data set” list is a record of available
datasets, where one of the lists is considered as “selected”. There are three types of data that can
be stored in the data set list namely: Tabular data set, Covariance matrix, and Correlation matrix.
We use Tabular data set. The Data wrapper is shown in Figure 2-2 below.

Figure 2-2: Data Wrapper shown
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Search Box:
TETRAD IV has a variety of search algorithms to assist in searching for causal explanations of a
body of data. The search algorithms read in data and return information about a collection of
alternative causal graphs that can explain features of the data. Some search algorithms can often
predict whether a particular variable influences another or not. Search algorithms do not output
an estimated model with parameter values; instead they output a description of a class of causal
graphs that explain statistical features of the data which were considered by the search
procedures. Some of the search procedures available are PC, CPC, PCD, FCI, etc which are
shown in Figure 2-3 below. We use PC technique which searches for Bayes net or SEM models
when it is assumed there is no unrecorded variable that contributes to the association of two or
more measured variables. The output obtained after execution of PC search algorithm is shown
in the Figure 2-4 below.

Figure 2-4: PC Search after execution
Figure 2-3: Available Search Algorithms
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Parametric Model Box:
A parametric model specifies the family of probability functions connecting cause and effect, but
does not specify values for its parameters. Two types of parametric models can be created using
TETRAD IV namely Bayes and SEM. If Bayes net is chosen, then the input graph to the PM box
will be parameterized as a categorical model in which the parameters are the unspecified
conditional probabilities of values of each variable on the values of its parent variables in the
graph. Bayes PM takes a DAG and adds to it, two bits of information (the number of categories
and the list of categories). If SEM is chosen, then the graph will be parameterized as a linear
Gaussian model with variances and linear coefficients. The Bayes PM is shown in the Figure 2-5
below.

Figure 2-5: Bayes Parametric Model

Estimator Box:
The Estimator box takes in information from the Parametric Model and the Data and outputs an
instantiated model. The procedures in the statistical estimator allow estimation of the parameters
based on the input data. Types of estimators include ML estimator, SEM estimator and Dirichlet
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estimator. There are also procedures for handling missing values in the input data. The ML
Bayes estimator is shown in the Figure 2-6 below.

Figure 2-6: ML Bayes Estimator

Instantiated Model Box:
An Instantiated model specifies particular numerical values for the parameters of a parametric
model. There might be three types of instantiated models namely Bayes instantiated model,
Dirichlet Bayes instantiated model, and SEM instantiated model. A Bayes instantiated model
extends a Bayes parametric model, specifying values of the parameters in the Bayes net. The
parameters for a Bayes net are the conditional probabilities stored in the conditional probability
tables, one for each variable in the Bayes net. The Bayes instantiated model is shown in the
Figure 2-7 below.
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Figure 2-7: Bayes Instantiated Model

Classify Box:
A Classifier box requires input from the Data and from IM box. It is used to classify new cases
with the Bayes net in the IM box. The user specifies a target variable in the IM and the classifier
uses the Bayes net structure of the IM to predict the values of the target in the data set. Statistics
on the classification accuracy are provided as ROC curves (shown in Figure 2-8), AUC and
confusion matrices (shown in Figure 2-9).
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Figure 2-8: ROC curve after classification

Figure 2-9: Confusion Matrix after Classification

2.2.3 Artificial Neural Network
Artificial neural networks are computing systems which try to mimic the elements and structures
of the nervous system in a summarized manner [50]. They were actually developed as a better
means of understanding the human brain and then they were used for roles like optimization [9].
In other words, if a neural network is given a large set of information, it can generalize from that
data by learning about it (training). This network is built on the strategy of train, test,
differentiate, and retrain on reduced gene set and then retest [10, 12].
An artificial neural network is a group of nodes and lines between the nodes where each node
depicts a neuron and the lines depict the relationship between the neurons. Strength of each
relationship is defined by a variable on which threshold can be applied to remove insignificant
relationships. These nodes and their interconnections are organized as layers. There will be an
input layer (to which the input is presented), a hidden layer (where all the processing is done on
the incoming data), and an output layer (where output is retrieved) as show in figure below.
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Figure 2-11: Training and Prediction Phases in a model built with Artificial Neural Networks [10]

Neural networks are particularly useful for classification analyses that are highly tolerant to
precision errors [11]. They can be used as alternatives to approaches which are limited by
assumptions of normality and linearity.
Good man and Harrell [9] discussed the advantages and limitation of using neural networks for
biostatistical modeling. They compared the neural network model with the generalized linear
model which is another popular biostatistical method. They found out that for binary outcomes
such as survival, cancer recurrence, etc. a link function is required to monotonically constraint
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the output prediction. The neural networks had efficient dimensional scaling but they had an
increased computational burden to optimize the model.
Boger [44] demonstrated the application of artificial neural networks for gene array analysis and
cancer cell identification. The data was first trained using a Principal Component Analysis
training algorithm and then local minima avoidance and escape algorithms were used. The inputs
were then ranked according to their relevance to the artificial neural network prediction accuracy
and the least relevant inputs were discarded. The remaining set of inputs was retrained to get
better prediction accuracy and this process is repeated.
Xu et al [45] discussed the method of distinguishing between two kinds of cancers using
artificial neural networks and gene filtering. In this method, the data was first clustered and it
was filtered using SAM gene filtering. The artificial neural network was then constructed based
on the principle of FeedForward with Error Backpropagation.
Keedwell et al [46] discovered a neural-genetic method which combines a genetic approach with
a supervised single layer artificial neural network to form a hybrid system. In this approach, they
formed a training set on which the gradient descent algorithm was applied via the artificial neural
network to determine the weights between the input genes and the output genes. The output is
tested for errors and the process is repeated until the errors meet the stopping criterion. They
experimented on the yeast S.cerevisiae data which consisted of 2468 genes.
Neural networks have been widely spread in various fields [9] such as pattern recognition,
speech synthesis, robotic control, etc. They can also be used to identify most relevant genes from
gene expression data, also to identify the high risk program modules [10] in software engineering
applications.
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Neural networks have a few limitations. Neural networks need a very huge training dataset to
generalize. If the dataset is not sufficiently large enough, the network model will be biased. They
cannot be used for data which do not have any correlation among the variables present in the
data. Moreover these networks need a lot of iterations to reach an approximation with minimum
errors. Since the iterative process is a time taking procedure, the amount of time required for
different networks is not always the same and hence it is a major shortcoming of neural
networks. Sometimes the neural networks might be over-trained which might lead to good results
only in the training but which actually don’t work for the test datasets. Neural networks are
difficult to understand and are not easily extensible. Neural networks are considered to be black
boxes [44] as the process that is going on in the hidden layer is not known to the user. Moreover
many applications of artificial neural networks include classification analyses but to our
knowledge, there are no applications for the complete modeling of gene-gene interactions yet.
2.2.4 Boolean Networks
Boolean networks are a kind of dynamic networks which are used to model gene regulatory
networks.
Sahoo et al [3] proposed a method for extracting the Boolean implications from large microarray
data. They analyzed the data from three species: humans, mice and fruit flies. They tried to
capture new relationships that were preserved in all the three species in spite of the differences in
various factors like tissue difference, gender differences, etc.
Boolean networks are limited to small scale networks. Since they are dynamic networks, it
becomes very difficult to model them at genome scale. This is due to the exponential increase in
computation with the number of entities [34].
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2.3

Implication Networks

Since all the above mentioned network-based approaches have a few limitations, another type of
network called the implication network is considered to build the interactions between the genes.
The algorithm to induce an implication network was first developed by Liu et al [1]. This
algorithm was based on binomial distribution. An alternative algorithm to induce the network
(which can be used not just with binomially distributed data as mentioned by Liu et al [1], but in
general to all implication networks built on either binomial or non-binomial data) was developed
by Guo et al [2] which was based on prediction logic.
Liu et al [1] described an algorithmic means for inducing implication networks from empirical
data samples. Several Monte-Carlo simulations were conducted to examine the effectiveness and
validity of the induction method. Dempster-Shafer belief updating scheme was used to predict
the values in implication networks.
Guo et al [2] proposed a novel methodology for predicting fault prone modules by using
Dempster-Shafer methodology. This methodology was applied on two case studies based on
NASA datasets and the performance of the methodology over other analyses was observed. The
prediction logic induced network in this paper has been used to build the implication networks
for our study.
In spite of the existence of many other network-based techniques, Implication networks were
used for this study. This is because they overcome the limitations of various other network-based
techniques. Implication networks are better than correlation networks in the sense that most of
the interactions between the genes in implication networks have comparable correlation
coefficients [3]. Thus it can be concluded that gene pairs with high correlation coefficients are
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almost always present in implication networks [3]. In addition, the accuracy of the correlation
networks decreases with increase in the size of the network and they cannot tolerate noise
accumulations. Thus gene networks with implication relationship are superior to those with
correlation relationship in terms of accuracy and stability of the classifier performance [7].
Moreover computing an implication network is not time taking as in the case of the neural
networks. They are simple to construct and are fast in terms of computation. The implication
networks do not need any prior learning regarding the implications, and their complexity does
not increase in an exponential manner and thus they overcome the limitations of Bayesian
networks.
A graph which involves nodes and arcs connecting each of the nodes in a directed manner is
called an implication network. In this network, each node represents a variable which might be a
gene or protein. Each arc between the nodes indicates the presence of a relation (a direct
implication like influence, binding, regulation, etc.) between the nodes (genes or proteins) it
connects. These arcs relate the values of each node with its parent nodes and child nodes and
these values are updated at regular intervals. The arcs are accompanied by weights which
represent the strength of the node relationships.
Contingency tables [2] are a tabular representation of categorical data which are used to record
and analyze the relationship between two or more variables. Thus it represents the strength of
association among the variables. In our network we used the contingency table to represent the
occurrences of errors in samples that are associated with the six possible implications.
An implication can be defined in the following manner [1, 2]. For

, If A is True, then B

is also True. If A is False, then B can be either True or False. So the erroneous case for
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would be A being True and B being False. This is shown below as positive implication in the
Figure 2-12 with a shaded cell. Similarly for

, the erroneous case would be both A and

B being True, which is shown as forward negative implication in Figure 2-12. Similarly inverse
negative implication and negative implication can be understood. For

, A and B should

both be True or both be False. So it combines the positive implication and the negative
implication to form the positive equivalence. Similarly for

, A and B should be

opposite to one another. This combines the forward negative implication and the inverse negative
implication to form the negative equivalence. Thus all the six relation types can be explained.

Figure 2-12: Six possible implications relating two variables [2]

The Contingency table that was used to calculate different values is shown below in Figure 2-13.
Each of the cells represents the errors that occurred while finding the implication between the
two variables.
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Figure 2-13: Contingency Table

The implication induction algorithm is shown in Figure 2-14 which was taken from Guo et al.
and a minimal

First significance level
,

1,

. Here

are set for each

,

0,

1 and

is the total number of attributes. Contingency table is

computed for all the possible sample cases and

that satisfy the condition on

is

computed for all relation types. This process is iterated till a solution exists and once a solution is
found the value is returned.
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Figure 2-14: Implication induction algorithm from Guo et al [2]

In this algorithm,

and

correspond to

and

respectively in our project.

They are the minimum scope and minimum precision that are required for the implication rule to
be considered as significant. They are calculated from simple Z-test for a cutoff value of

1.64 .

These values keep varying with the number of samples in the group.
All the values of

and

are calculated as shown below [2].

is the total number of

samples.

(2.5)
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(2.6)

(2.7)

(2.8)

The first four values of

1

(2.9)

1

(2.10)

1

(2.11)

1

(2.12)

relate to each of the unsymmetrical implications. The values of

for symmetrical implications can be found by combining values of two each of the
unsymmetrical implications as shown below.

(2.13)

(2.14)

The implications are associated with two weight functions that specify the strength of the
relationship between the pair of nodes that are connected. These weight functions can thus be
defined as shown below [1, 2].
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0,1

(2.15)

0,1

(2.16)

Thus they can be defined in terms of the contents of the contingency table as below.

(2.17)

(2.18)

Thus if is a complete set of possible implication rules which can be generated,
type,
node

and

are the weight functions that map the precedent node

is the relation

and the consequent

, then an implication rule can be generalized as follows [2].
,

,

,

,

,

(2.19)

Implication networks extract many more relationships among the variables that are overlooked
by most of the current approaches. Most of the currently existing approaches concentrate only on
the relations which have same states for both the variables like in the cases of positive
equivalence and negative equivalence. But there might be some very significant connections in
the implication networks which are not significantly correlated. The implication networks have
the capability to identify many known biologically phenomena and also to extract hierarchical
relationships. They are also stable over various species.

2.4

Survival Analysis

To validate the prognostic signatures identified in the network-based approach, survival analysis
is performed on them. Survival Analysis is normally done with respect to the occurrence of an
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event (which is normally death of the patient) with time. It helps in finding out what portion of
the considered group survives past a certain time. It also gives the rate of increase or decrease of
the occurring event. Survival Analysis is done using the following methods
1. Time dependant ROC analysis and Random Test
2. Cox Proportional Hazards Model
3. Kaplan-Meier Plots
4. Multivariate Analysis using Cox Proportional Hazards Model
2.4.1 Time dependent ROC analysis and Random Test
ROC curves are techniques used for visualization, organization, and selection of classifiers based
on their performance. They are plots between sensitivity and (1-specificity). Time dependent
ROC analysis is said to be done when ROC (Receiver Operating Characteristics) curves are
varied as functions of time . Since most of the disease outcomes are dependent on time, Time
dependent ROC analysis becomes more apt.
ROC curves are capable of portraying the differentiation capacity of a test even without
considering a specific threshold [16]. Even when the diagnostic markers are on diverse scales of
measurement, ROC curves provide a convenient method for comparison. AUC or the Area under
the Curve [17] is also considered as an important standard of comparison. It can be considered as
the metric that compares the probability of diseased states to non-diseased states and thus
summarizes the ROC curve. Since ROC is a two-dimensional representation of the classifier
performance, it can be reduced to a single scalar value as AUC representing the expected
performance. Thus realistic classifiers should not have AUC value less than 0.5. Since ROC
graphs are conceptually very simple, they can be used as cost-sensitive learning techniques.

33

If

is the explanatory variable or predictor, and

any time . If a cutoff point

is the event (which is death in our case) at

is considered which keeps varying, then the sensitivity and

specificity would be functions of

and . Thus the sensitivity and specificity can be expressed as

[16]

Thus

|

1

(2.20)

,

|

0

(2.21)

curve is a graph plotted between

curve) and 1
for each

,

,
is defined as

,

(it is the Y-axis in the ROC

(it is the X-axis in the ROC curve). The area under the curve
.

In Random Test, gene signatures are picked randomly and their performance is compared with
the performance of our gene signature. Thus it acts as a measure of the significance of our
signature when compared to some signatures picked randomly.
2.4.2 COX Proportional Hazards model
Cox Model was a regression model described by D.R.Cox in his paper, “Regression Models and
Life-Tables” [18] in 1972. Since then till to date, Cox model is a well-recognized statistical
technique which explores the relationship between survival times and several other predictors
(also called covariates or explanatory variables) simultaneously [18]. In other words, it gives an
estimate of the treatment effect on the survival after adjusting the covariates and also to estimate
the risk of death. Cox model has many coefficients. For each variable these coefficients describe
whether a patient is under poor prognosis or a good prognosis.
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Cox model helps in isolating the effects of treatment from the effects of other variables or
covariates. It helps in improving the treatment effect as it narrows down the confidence interval.
Survival times are censored if the patients followed up for several years are still alive after the
end of study. Their survival time is not known from their surgery, as it is even longer than the
time in study.
The regression model introduced by Cox is also known as proportional hazards regression
analysis as it is used to explore several variables at a time. The hazard function is the probability
that a patient will experience an event within a small interval of time, and therefore it can be
understood as the risk of dying at time t. The hazard function denoted by h(t) can be estimated
using the equation [19]. If two observations are considered as shown below, the hazard ratio of
these two observations is shown in the last equation.

(2.22)

h t

h t

exp β . x

(2.23)

h t

h t

exp β . x

(2.24)

h t
h t

exp β . x
exp β . x

(2.25)

2.4.3 Multivariate Analysis using COX Proportional Hazards model
Regression is a statistical technique used to explain the relationship between the values of two or
more variables. When more than one variable needs to be taken into account, the method is
called multiple regression technique (multivariate analysis) which is almost the same as Cox’s
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model except that Cox model allows considering in to account more than one explanatory
variable at any one time. Thus hazard [19] at any time t can be expressed as
h t

h t

exp β

. age

β

. duration

β

. location

(2.26)

. duration

β

. location

(2.27)

By applying natural logarithms, we get
ln h t

ln h t

β

. age

β

Thus h t is the underlying hazard function or baseline hazard. The coefficients such as
β

,β

,…,β

are the regression coefficients and they constitute the proportional

change that can be expected in the hazard or risk function related to the other variables which are
estimated by a statistical method called the maximum likelihood technique.
Consider two observations of hazards at times i and .
h t

h t

exp β

. age

β

. duration

β

. location

(2.28)

h t

h t

exp β

. age

β

. duration

β

. location

(2.29)

The hazard ratio for the above two would be [19]
h t
h t

exp β
exp β

. age
. age

β
β

. duration
. duration

β
β

. location
. location

(2.30)

Thus it can be seen that the hazard ratio does not depend on the baseline hazard. Proportional
hazard is the assumption of a constant relationship between the dependent variable and the
explanatory variables. Cox regression analysis will result in a final model which yields an
equation for hazard as a function of the several covariates.
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2.4.4 KaplanMeier Plots
The Kaplan-Meier curves, which are also known as product limit estimators, help in estimating
the survival function from life time data.
From a set of survival times, the proportion of the population who would survive a given length
of time under the same circumstances can be estimated using the Kaplan-Meier [48] (or product
limit) method. A plot of the Kaplan-Meier estimate of the survival function is a step function.
The estimated survival probabilities are constant between adjacent death times and they only
decrease at each death.
is the number of samples at risk just prior to time

If

and

is the number of deaths at time

, then Kaplan-Meier estimate would be the nonparametric maximum likelihood estimate of
, which is the probability that a sample from the given population would have a lifetime
exceeding , which can be shown as below.

(2.31)

2.5

Prognostic Validation

Prognostic validation is usually done to predict the chance of recovery of a patient. Prognosis is
normally estimated with the help of variables such as sensitivity, specificity, hazard ratios and
log-rank p-values. Prognostic validation is done using the following methods
1. Overall Accuracy
2. Concordance Probability Estimate
3. Gene Set Enrichment Analysis
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2.5.1 Overall Accuracy
There are many metrics such as likelihood ratio, area under receiver operator characteristic
(ROC) curve, overall accuracy, etc. which integrated both sensitivity and specificity to describe
the validity of models or tests. Overall Accuracy is a single summary metric which is calculated
from the 2

2 contingency tables which is the overall probability that a patient will be correctly

classified by a model. A 2

2 contingency table is shown below.

Accuracy =

=

(2.32)

Accuracy = (Prevalence) (Sensitivity) + (1-Prevalence) (Specificity)

(2.33)

Sensitivity is the probability that a person with the disease tests positive. Specificity is the
probability that a disease-free person tests negative. Disease prevalence refers to the ratio of the
number of patients with the disease and the total number of patients considered. Overall accuracy
is the probability that a patient tests positive when he has the disease and tests negative when he
is disease free; that is, the sum of true positives and the true negatives divided by the total
number of patients. In other terms it can be shown to be the weighted average of the sensitivity
and specificity where sensitivity is weighted by prevalence and specificity is weighted by the
complement of prevalence. Thus the formulae for Sensitivity, Specificity and Overall Accuracy
when a 2

2 contingency table is considered are shown above.
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Overall accuracy as a measure has a limitation in the sense that it is prevalence dependent which
sometimes gives a misrepresented idea of the validity of the model.
2.5.2 Concordance Probability Estimate (CPE)
Concordance probability is used to estimate the distinguishing power and the predictive accuracy
of statistical models. CPE forms a stable estimator of predictive accuracy which can be
computed easily. The proposed estimator for CPE is a function of regression parameters and the
covariate distribution and is asymptotically unbiased. A concordance probability of 1.0
represents a model that has perfect discriminating capacity where as a CPE of 0.5 indicates that
the model is not good enough as it cannot discriminate between the observations in an accurate
,

manner. If two observations (

) and (

,

) are considered, then their concordance

probability [29] is defined as below.
|

,

(2.34)

If the value of CPE is less than 0.5, it does not mean that the model is bad, but it may be
considered as below by taking –

instead of

as a predictor of

to obtain a CPE higher than

0.5.
1
If

|

,

|

(2.35)

is the baseline hazard function independent

is a p-dimensional covariate vector, and

of the covariates, and

,

is the vector of the regression parameters, then the hazard function

of Cox proportional hazards model is given by
|

exp
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(2.36)

CPE is a simple function of the Cox proportional hazards model and is not sensitive to the degree
of censoring and does not require imputation of survival times.
The proportional hazards conditional survival function which determines the relationship
between the p-dimensional covariate vector

and the survival time is given by

; ,

exp

(2.37)

The ordering between the survival times of two subjects with log relative risks

and

under proportional hazards can be measured by

;

,

;

1

,

|

Thus concordance probability

(2.38)

1

may be written as

1

(2.39)

for integrals ranging over the interval
covariate linear combination

and

is the distribution function of the

.

The concordance probability estimator [29] can be given as
0

2
1

where
and

1

exp

is the partial likelihood estimator for
represents the pairwise difference

0
1

exp

(2.40)

and empirical distribution function was used for
.

40

In R, a package for CPE exists which includes a command named “phcpe”. This command is a
function used to calculate the Gonen & Heller concordance probability estimate (CPE) for the
Cox proportional hazards model. It outputs the CPE and the standard error of the CPE. The input
for phcpe is a Cox fit model. Since a Cox fit model is present, we get various outputs such as pvalues from log-rank tests, hazard ratios and the confidence intervals also as outputs from phcpe.
The CPE values must always be greater than 0.5 for a data to be significant. The higher the CPE
values, the more significant the data is considered to be. Similarly, p-values from log-rank tests
must be lesser than 0.05 and hazard ratios must be greater than at least 1.
2.5.3 Gene Set Enrichment Analysis (GSEA)
Gene Set Enrichment Analysis12 is a powerful analytical method that computes whether a
predefined set of genes is statistically significant and whether the gene set has agreeable
differences between the two phenotypes (biological states). GSEA interprets gene expression
data and focuses on the gene sets as a whole. It generates analysis based on the groups of genes
that share common biological function, chromosome location or regulation.
GSEA [30] works in three steps:
1. Calculation of an Enrichment Score (ES): ES is the maximum deviation from zero
encountered in a random walk which corresponds to the Kolmogorov-Smirnov-like statistic.
It is calculated to show whether the gene set is overrepresented at the top or bottom of the
ranked list.
2. Estimation of the significance level of ES: The nominal P value of the enrichment score
which denotes its statistical significance is estimated by using an empirical phenotype-based
permutation test. The permutation of phenotypes preserves the complex correlation structure
12. http://www.broadinstitute.org/gsea/
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of the gene expression data which provides a more biologically reasonable estimation of
significance.
3. Adjustment for Multiple Hypothesis Testing: After the complete database of gene sets is
assessed, the estimated significance level is adjusted to account for multiple hypothesis
testing by calculating the normalized enrichment score (NES) and the false discovery rate
(FDR). FDR is the estimated probability that a gene set with a given NES represents a false
positive finding.

2.6

Topological Validation

Structural validation is done using the following methods
1. PRODISTIN13
2. PubMed14
3. NCI Pathways15
4. KEGG16
5. MATISSE17
6. STRING 818
7. Ingenuity Pathway Analysis19
8. Pathway Studio20
2.6.1 PRODISTIN
PRODISTIN method functionally classifies genes or proteins from all types of interaction
networks according to the identity of their interacting partners. It can also be used to obtain
information related to protein function and to relationships linking cellular processes [22].
Proteins can be compared functionally at the cellular level or the molecular level. In
13.
14.
15.
16.
17.
18.
19.
20.

http://crfb.univ-mrs.fr/webdistin/
http://www.genome.jp/kegg/
http://pid.nci.nih.gov/
http://www.ncbi.nlm.nih.gov/pubmed/
http://acgt.cs.tau.ac.il/matisse/
http://string.embl.de/
http://www.ingenuity.com/
http://www.ariadnegenomics.com/products/pathway-studio/
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PRODISTIN method, proteins are clustered according to their cellular processes more efficiently
rather than the molecular or the biochemical functions. The result of PRODISTIN method on
interaction networks allows the user to acquire a classification tree in which network
genes/proteins are grouped according to their functional similarity and to find out functional
classes in the tree using the biological process Gene Ontology annotations of genes/proteins. The
basic concept is that the more two proteins share interacting partners, the more they should be
functionally related.
PRODISTIN method consists of two different and successive bioinformatic steps as shown in
Figure 2-15 below. Initially a graph including all proteins connected by a specific relation is
constructed and Czekanowski-Dice distance is calculated between all possible pairs of proteins
in the graph with respect to the interacting partners they share. This classical distance on graphs
corresponds to the formula [22].

,

#

∆

#

#

(2.41)

where i and j denote two proteins, Int(i) and Int(j) are the lists of their interacting partners plus
themselves (which are used to decrease the distance between the proteins interacting with each
other) and ∆ is the symmetrical difference between the two sets. In other words it gives sum of
the interactors in both minus twice the number of common interactors between the two
interacting proteins. This distance was chosen because it increases the weight of the shared
interactors by giving more importance to the similarities than to the differences and also it
authorizes the use of tree representation. For two proteins that do not share any interactors, the
distance is 1 and is the maximum value. For two proteins interacting with each other and sharing
exactly the same interactors, the distance is 0 and is the minimum value. The second step would
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be to cluster all the distance values according to BioNJ, which would lead to a classification tree.
The tree can be visualized and subdivided in to formal classes according to the biological process
in Gene Ontology annotations.

Figure 2-15: Step wise procedure for PRODISTIN method [21]

PRODISTIN has the ability to predict correctly, the function for unknown proteins and it shows
reliability even in the presence of both spurious and missing interactions in the dataset. It can
also be used to investigate the evolution of the function of duplicated genes. As more interactions
become available, it improves the relevance of the protein clusters found by the PRODISTIN
method. The PRODISTIN web interface is shown in Figure 2-16.
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Figure 2-16: PRODISTIN website

2.6.2 PubMed
PubMed was developed by National Centre for Biotechnology Information (NCBI) at National
Library of Medicine (NLM) located at U.S. National Institutes of Health (NIH). It is available
through Entrez retrieval system. It helps search in biomedical citations and abstracts. PubMed is
a search engine that allows access to many databases including the MEDLINE database of
journal articles. Its focus is on medicine and related fields like nursing.
PubMed can be searched for required details in many ways as shown below in Figure 2-17. Any
data required can be searched in entire PubMed or it can be restricted to some fields such as
genes, proteins, journals, etc. The results could be even more focused by choosing the limits of
search such as the organisms, taxonomy, etc. It is one of the web based search engines which is
used widely by biostatisticians to extract gene information.
Advanced search is also available which allows finding data by author’s name, publication date,
title, etc. as shown below in Figure 2-18. The recent items searched are also stored and they can
be revisited when required. PubMed has an option called LinkOut which allows to access
resources in external websites directly from the PubMed database. LinkOut resources include
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research tools, full text publications, biological databases, etc. Thus instead of searching various
databases each separately, it would be sufficient to check in PubMed which give links to all the
other databases if they are present. The links are present in such a way that we could access just
the abstract or the entire text in required format (text or pdf).

Figure 2-17: PubMed website

Figure 2-18: Advanced Search in PubMed
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2.6.3 NCI Pathways (Pathway Interaction Database)
National Cancer Institute (NCI) is a part of the U.S. National Institutes of Health and supports a
national network of cancer centers and supports research projects in cancer control. Nature
Publishing Group (NPG) is a publisher of 60 prestigious scientific journals including the highly
impact Nature, the international weekly journal of science. A collaborative project between NCI
and NCI is the Pathway Interaction Database (PID).
PID is a highly structured database which includes a curated collection of information. The
schema of the database is very flexible which makes it easy to store a wide range of information
about cell signaling pathways. It includes known biomolecular interactions that are taking place
in human cells and also includes key cellular processes which when combined make up signaling
pathways. PID shows not only the predefined pathways but also interaction networks that are
dynamically constructed. Since the editorial section of PID also includes outlines of recent
research articles connected to cancer, it acts as a practical advice and tool to bioinformaticians
and biologists.
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Figure 2-19: Pathway Interaction Database

Figure 2-20: Browsing Pathways in PID
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PID includes many pathways extracted from three types of data as shown in Figure 2-19 and
Figure 2-20. They are NCI-Nature Curated data, BioCarta data and Reactome data. NCI-Nature
Curated data are produced by Nature Publishing Group according to a few principles. They
include Human Model System, Biological relevance, Authority and Consistent nomenclature.
BioCarta was imported in to PID in June 2004 and Reactome was imported in December 2007.
In NCI-Nature Curated data and Reactome data, biomolecules are annotated with Uniprot protein
identifiers and relevant post-translational modifications whereas in BioCarta data, biomolecules
are annotated by Entrez gene identifiers without post-translational modifications.
A biologically meaningful set of interactions is defined as a pathway in PID. Molecular
interaction is the basic unit of representation in PID. Thus the information is very fine-grained
and highly structured. In each interaction, each biomolecule is identified along with the nature of
process (biological events) it is involved and its role in each of the processes. Pathways are
portrayed graphically labeled nodes and edges. Additional references are also provided.
2.6.4 KEGG
KEGG stands for Kyoto Encyclopedia of Genes and Genomes. It was initiated in May 1995 to
computerize the knowledge of molecular and cellular biology in terms of information pathways
that consist of interacting genes or molecules. Its objective was to link [24] the structural data
obtained by genome projects and the functional data. KEGG was built based on the pair wise
interaction of genes or molecules. Since information regarding known pathways has been
expanding rapidly, it has become necessary to computerize known pathways at the time of
KEGG’s initiation. KEGG was considered to be an effort to advance concepts and technologies
and real time data collection efforts [26]. KEGG contains an aspect of the deductive database
where new interactions could be deduced from relations stored in database. Thus the basic
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concept of KEGG is the relation and deduction. KEGG has a hierarchy which is important in the
sense that it represents functional, structural and evolutionary relationships of genes and
molecules. The advancements in the database and networking technology make KEGG even
better in the aspect of its functionality especially the deductive and object-oriented databases.
KEGG consisted of three databases [23, 25] when it started. KEGG PATHWAY represents
higher order functions in terms of the network of interacting molecules (mostly proteins). It is a
set of manually drawn pathway maps which represent knowledge on the molecular interaction
and reaction networks and also on structural relationships. The best organized part of
PATHWAY is that the organism specific pathways are constructed computationally by
correlating genes in the genome with gene products in the reference pathways according to the
matching EC numbers. Gene catalogs for all the completely sequenced genomes and some partial
genomes are accumulated under KEGG GENES. The number of GENES’s entries keeps
increasing every year to keep track of the updating genome sequences. Thus GENES acts as a
gateway to a number of other resources containing more detailed information. KEGG LIGAND
is the collection of chemical compounds in the cell, enzyme molecules and enzymatic reactions.
It is a composite database which includes COMPOUND, DRUG, GLYCAN, REACTION,
RPAIR and ENZYME databases. KEGG BRITE was added later which depicts the hierarchical
classifications.
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Figure 2-21: KEGG Website

Figure 2-22: KEGG PATHWAY

51

KEGG was later updated with many other databases which came up to 19 databases categorized
in to systems information, genomic information and chemical information. KEGG website can
be seen in Figure 2-21 and KEGG PATHWAY is shown in Figure 2-22 above.
2.6.5 MATISSE
MATISSE is a program that implements a novel computational method for efficient detection
and analysis of JACSs. JACSs are Jointly Active Connected Subnetworks which are the
functional modules that are sought by identifying the connected subnetworks in the interaction
data that exhibit high average internal similarity [27]. MATISSE has a statistical basis, which
allows confidence estimation of the results and no prior knowledge of the JACSs is required
which removes the requirement of precalculation of the statistical significance of expression
values. Thus it suits all types of network data overlaid with pair wise similarities.

Figure 2-23: MATISSE interface

Figure 2-24: Choosing the Algorithm
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Figure 2-25: Displaying the module

MATISSE needs to choose a species first and then the interaction network and the expression
data must be loaded as shown in Figure 2-23. After the data is loaded, modules must be found
and for that the Algorithm which must be used to find the modules must be selected as shown in
Figure 2-24. The displayed modules can be filtered by applying filters which is shown in the
Figure 2-25.
MATISSE detects non-overlapping JACSs by identifying heavy subgraphs in an edge-weighted
similarity graph while maintaining connectivity in the interaction network. There are three
phases in the detection and analysis of JACSs: (1) relatively small, high-scoring gene sets, called
seeds must be detected; this detection can be done by any of the methods such as Best-neighbors
or All-neighbors or Heaviest-subnet, (2) Seed improvement or greedy optimization; this
optimization can be done using the methods like Node addition, Node removal, Assignment
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change, and JACS merge, (3) significance-based filtering; the empirical p-value of the score was
calculated for each JACS and a threshold of p=0.05 is applied.

Figure 2-26: Module from MATISSE

Figure 2-27: Module from Co-clustering method

In MATISSE, modules are also generated using Co-clustering method for the purpose of
comparison. Co-clustering methodology uses a distance function that combines similarity of
gene expression profiles with network topology. A few properties include Expression
homogeneity (calculated as the Pearson correlation between genes within the same module),
edge density (number of edges it contains as a fraction of all its node pairs), and clustering
coefficient (fraction of a node’s neighbor pairs connected in the network). MATISSE is designed
to produce connected subnetworks as shown in Figure 2-26 whereas Co-clustering generates
modules that are highly disconnected as shown in Figure 2-27 above. Thus MATISSE is much
better [27] in all the properties checked for comparison with Co-clustering technique.
2.6.6 STRING 8
STRING 8 stands for eighth version of Search Tool for the Retrieval of Interacting
Genes/Proteins. It is a database and web resource that constitutes most of the available proteinprotein interactions, scores and weighs it and escalates it with not only predicted interactions, but
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also with the results of automatic literature-mining searches. The latest version of STRING 8
covers almost 2.5 million proteins from 630 organisms and thus it provides a very
comprehensive view of the protein-protein interactions. It includes resources from various other
sources such as MINT, HPRD, BIND, DIP, BioGRID, KEGG, Reactome, IntAct, EcoCyc, NCINature Pathway Interaction Database, and Gene Ontology (GO) protein complexes, etc. Apart
from the interactions previously known interactions from the above resources, STRING 8 uses a
number of prediction algorithms that computationally predict many more interactions. It searches
for genes that are found in close surroundings of chromosomes as it would be a good indication
of functional relation. It then searches for instances where genes join to encode a single fusion
protein. It also searches for gene families that have similar phylogentic profiles and also genes
that are co-expressed under different conditions. It includes interactions identified from text
mining of databases like SGD, OMIM, The Interactive Fly and all the abstracts of PubMed.
STRING 8 is more fault tolerant when clustering conserved neighborhoods by ignoring false
predictions.
The network images in STRING are generated using a spring model where nodes are taken as
masses and the edges are considered as springs.
In STRING 8, one or more proteins of interest are entered as inputs by giving names or
identifiers as shown in Figure 2-28. The appropriate organism is selected. STRING 8 also has a
random input generator which will select randomly a gene/protein with a minimum of 4
predicted links above medium confidence or even better. Prediction summary is obtained for the
proteins that were given as input. All the predicted relations are sorted by their scores and each
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of them can be viewed in detail. The various types of evidence supporting the predicted
associations can be viewed by clicking the different views of the data.

Figure 2-28: STRING 8 web interface

The network view briefly summarizes the interactions between the proteins with each of the
protein as a node in the network. Any two proteins may be connected using seven different
colored functional associations where each color indicates the presence of one evidence. A red
line implies presence of fusion (individual gene fusion events per species) evidence; a green line
implies conserved neighborhood (genes that occur repeatedly in close neighborhood in genomes)
evidence; a blue line implies co-occurrence (presence or absence of linked proteins across
various species) evidence; a purple line implies experimental (list of significant protein
interaction datasets acquired from other protein-protein databases) evidence; a yellow line
implies text mining (list of significant protein interaction groups extracted from the literature)
evidence; a light blue line implies database (list of significant protein interaction groups acquired
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from curated databases) evidence; a black line implies co-expression (genes that are coexpressed in the same species or other species) evidence. Clicking on a node gives many details
about the protein and clicking the edge gives all the different scores relating to each of the
evidences.
2.6.7 Ingenuity Pathway Analysis
Ingenuity Pathway Analysis (IPA) integrates data from a variety of experimental platforms. It
provides insight into molecular and chemical interactions, cellular phenotypes, and disease
processes of our system. IPA is built upon a huge foundation of scientific evidence which
include journal articles, textbooks, and other data sources. It presents the data in a meaningful
visual and knowledgeable way.
There are different types of analyses that can be performed on a group of genes. They include
Core analysis, IPA-Tox analysis, IPA-Metabolomics or IPA-Biomarker analysis. These analyses
in most cases give a good indication of what cellular processes the given dataset is related to.
Core analysis is used to interpret datasets in the context of biological processes, pathways and
molecular networks. IPA-Metabolomics analysis analyzes the metabolite data about cell
physiology and metabolism. IPA-Tox analysis assesses the toxicity and safety of the compounds
of interest. It also shows the appropriate toxicity phenotypes and clinical pathology endpoints
related to a dataset. IPA-Biomarker analysis identifies and prioritizes the most appropriate and
promising molecular biomarker candidates from the datasets. Each of these analyses can be run
multiple times on different inputs and they can be compared among themselves using
Comparison analyses which help in understanding which of the samples are more relevant to
each condition.
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Ingenuity systems have a database that is highly structured and context-rich which makes it
unique among the different pathway applications. All the results found in IPA are always
supported by experimental results and thus are not just based on the occurrence in few abstracts.
These results are structured in to an ontology which lets the use of very powerful computational
algorithms that presents the results in IPA when queried.
IPA includes many features such as integrated broadband coverage of systems biology (including
protein, gene, protein complex, cell, cellular component, tissue, organ, small molecule, and
disease interrelationships), broad genome wide coverage of human, mouse, and rat genes, huge
number of pathway interactions extracted from literature, very systematic capture of canonical
pathway relationships and almost up to date literature.
IPA uses different shapes for the nodes in the networks and different types of connectors
between the nodes for different types of relationships between the genes or proteins as shown in
Figure 2-29.
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Figure 2-29: Different Network and Path Designer shapes along with Relationships used in IPA to represent
different types of data

It is not an open source and hence a license is needed to use the entire version of IPA. There is a
free trial version but it does not include all the pathways and hence same results are not obtained
each time it is used.
2.6.8 Pathway Studio
Pathway Studio is a combination of three products:
1. ResNet database
2. MedScan application
3. Pathway Studio interface
ResNet is a database that comprises of the biological relations, ontologies and pathways that
were compiled by the Ariadne scientists for Mammalian (Human, Rat, and Mouse) and Plant
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research. This database stores information that has been successfully extracted from PubMed in a
manner such it allows searching, retrieving and even updating of the database by the user.
Moreover the extracted interactions have access linked to the original data source. All possible
aliases are also included which excludes redundancy and thus maintains identity of the genes.
MedScan is a computational approach used for data analysis that has the information from
literature as a coherent and integrated part within it. It is like a web search engine which not only
gathers knowledge about a query but also scans the literature for relationships and highlights
those relationships in the articles that were gathered. It also lists all the relationships and
molecular processes in appropriate tables which can be saved in to the ResNet database and
reused for further analysis. MedScan has access to PubMed and 47 full-text journals and
additional journals may also be added from different sources. MedScan can thus create many
databases of specific organisms, diseases, etc and it can highlight different proteins, chemicals,
cell processes, etc in literature. MedScan is used to update ResNet database and this can also be
automated.
Pathway Studio is a software which analyses gene expressions and builds pathways. These
pathways can be expanded and various relationships between genes, proteins, diseases, etc can
be extracted. It works together with ResNet database (and MedScan reader to update the
database). Once the experimental data is imported in to Pathway Studio, it enables in-depth
analysis of the data and relationships are extracted from the literature (PubMed). By changing
the settings in Pathway Studio, it can find common regulators and relates pathway components
with biological entities of similar functionality.
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Figure 2-30: Different shapes and colors used in Pathway Studio to represent for different types of data

There are 227 receptor signaling and 21 new cellular process regulation pathways that are
included in Pathway Studio. These can be further expanded using MedScan. Pathway Studio is
not an open source and license is needed to use it.

2.7

Summary

This chapter discussed the advantages of network-based techniques over feature selection
methods. Feature selection procedures considered the behavior of each gene individually. Hence
this chapter highlighted the importance of considering the “gene interactions” instead of each
gene individually. It also reviewed the various network-based techniques such as correlationbased and clustering-based coexpression networks, Bayesian networks and artificial neural
networks. The literature study of these techniques was summarized. The limitations of the
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network-based techniques have been discussed. The correlation-based coexpression networks
and the clustering based coexpression networks do not provide predictive structure or causal
relations. Moreover their accuracy decreases with increase in network size. Bayesian networks
cannot contain loops and they require subjective priors. Neural networks are time consuming and
have the possibility of overtraining. It was thus discussed that all these limitations have been
overcome by the implication networks. Algorithm of the implication network that was used in
identifying the gene signatures was explained. Different validation techniques and tools, used for
both prognostic and topological validation of the signature identified from the implication
network were discussed.

62

Chapter 3

3 Networkbased approach for identification of prognostic signatures
3.1.

Introduction

In the earlier chapter, major limitations of the compared network techniques along with the
advantages of implication networks were emphasized. In this chapter, details will be focused on
how implication networks were applied on the dataset and how gene signatures were identified.
Moreover descriptions of the datasets, procedures and results obtained from the application of
implication networks are provided.

Figure 3-1: Flow chart of the methodology
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The flow chart of the methodology is shown in the Figure 3-1 above. The first top box of the
flow chart as displayed constitutes the identification of the gene signatures and this part will be
discussed in this chapter. Details of survival analysis will also be given in this chapter.

3.2.

Methodology for identifying prognostic gene signatures

Identification of the gene signature is done on the training dataset and the validation of the
obtained signature is performed on the test datasets.
The gene expression data of the training dataset is divided in to two or more groups based on
some variables such as survival time, survival status, smoking status, etc. In this thesis, survival
time and survival status are used together to split the data in to two groups. These groups are
named Metastasis group (high risk group) and Non-Metastasis group (low risk group).
Interactions among the genes are induced using prediction logic algorithm [1, 2]. Thus genome
wide networks for both the groups are generated. After we get interactions among the genes in
both the groups (Metastasis and Non-Metastasis), differential components between the groups
are picked. Differential components are the set of interactions that are present in one group but
are not present in the other group and vice versa. In other words, differential components of
Metastasis group are unique and similarly, differential components of Non-Metastasis group are
unique. Thus we get the interactions that differentiate the high risk group and the low risk
groups.
Once the differential components are found, all the genes interacting with the major cancer
hallmarks are picked. Major cancer hallmarks are genes that were already known to be of great
importance in cancer research. Since these genes are known to have strong interactions with
other genes in the cancerous conditions, we consider that the genes, which interact with all these
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genes, might be in one or the other manner, included in the regulation or progression of tumors.
Hence the set of genes that interact with all the major cancer hallmarks are considered to form a
signature. By varying the set of hallmarks, we get different signatures.
Once signatures are found, we validate these signatures to find a signature that outperforms the
other signatures and later evaluate the better signature prognostically and topologically (this will
be dealt in the next chapter).
3.2.1 Datasets Information
The data required for acquiring, training and testing the signatures was taken from a consortium
[20] which was formed with the support and collaboration of US National Cancer Institute
investigators. The dataset is a combination of samples collected from four institutions [20] using
a common platform. The institutions that formed the consortium include University of Michigan
Cancer Center (UM), Moffitt Cancer Center (HLM), Memorial Sloan-Kettering Cancer Center
(MSK) and the Dana-Farber Cancer Institute (CAN/DF). The data from UM had 177 samples,
HLM had 79 samples, CAN/DF had 82 samples and MSK had 104 samples. There were a total
of 442 samples and 22215 genes. The data from UM and HLM were combined to form the
Training dataset which has 256 samples. This Training dataset was used to find signatures and
then they were validated on the remaining two datasets (CAN/DF and MSK).
3.2.2 Dataset processing
The Training dataset consists of 22215 genes and 256 samples. There were duplicate probes for
many genes. The duplicate probes of every single gene were averaged. This narrowed down the
number to be 13658 unique genes. This data was split in to 2 files, Metastasis (High risk) and
Non-Metastasis (Low risk) groups, based on the number of months the patients survived and
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their survival status. If the number of months the patients survived was greater than 60 (5 years),
the sample was put in Non-Metastasis group (Low risk). If the number of months the patients
survived was less than 60 months and if it was known that the patient died, the sample was put in
Metastasis group (High risk). If the number of months the patients survived was less than 60
months and if it was not known whether the patient died, the sample was censored. The
Metastasis group (High risk) consisted of 125 patients and the Non-Metastasis group (Low risk)
consisted of 104 patients. There were 27 samples that did not fall in to either of the groups and
hence they were censored. Then the data values were converted in to binary values (0’s and 1’s)
based on the mean of the expression values of each gene. The mean values were calculated using
bootstrapping so that the impact of the number of samples being different does not affect the
value of the mean. If the expression value of each gene for each sample was less than or equal to
the mean of all samples for that particular gene, it was defined as 0 and if it was greater it was
defined as 1.
3.2.3 Deriving genome scale gene interactions
The interactions between the 13658 genes in each of the groups containing 125 (for metastasis
group) and 104 (for non-metastasis group) samples were derived. The underlying principle in
generating the gene interactions is based on prediction logic used for inducing the implication
network [1, 2]. The minimum scope and minimum precision required were calculated using
simple Z-test for a cutoff value of 1.64. There were 159,402,305 interactions that were derived
from the Metastasis group (High risk). There were 154,144,728 interactions that were derived
from the Non-Metastasis group (Low risk). The comparison of the number of interactions from
both the groups is shown below in Figure 3-2.
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3.2.4 Identifying Differential Components
After the genome wide interactions for the dataset were obtained, the differential components of
each of the groups were obtained. Differential components are the gene interactions of one group
that are not present in the other group. The interactions present in Metastasis group (High risk)
but not present in the Non-Metastasis group (Low risk) are called the differential components of
Metastasis group (High risk). Similarly, the interactions present in the Non-Metastasis group
(Low risk) but not present in the Metastasis group (High risk) constitute the differential
components of the Non-Metastasis group (Low risk). In other words they are the interactions that
differentiate the two groups from one another. There were 91,445,437 common interactions
between the groups. Thus there were 67,956,868 differential components for Metastasis group
(High risk) and there were 62,699,291 differential components for Non-Metastasis group (Low
risk) were. The comparison of the differential components from both the groups along with the
genome wide interactions is shown below in Figure 3-2.

Figure 3-2: Bar graph showing the number of interactions in Poor (high risk) and Good (low risk) prognosis
for genome wide interactions and differential components in the Training dataset
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3.2.5 Major Cancer Hallmarks used to identify prognostic markers
Major Cancer Hallmarks are the genes which are considered to be important. A different set of
hallmarks can be considered to find different signatures. Gene signatures are picked from the
genes which have interactions with all the hallmarks. There were 7 hallmarks that were
considered to find gene signatures. Six of them were EGF, EGFR, KRAS, MET, RB1, and TP53.
The seventh hallmark E2F had five different probes E2F1, E2F2, E2F3, E2F4, and E2F5. Hence
they totaled to 11 hallmarks.
3.2.6 Identifying Gene Signatures
All the genes which had interactions with the entire set of 11 hallmarks were picked from both
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 7 genes
from the Metastasis group (High risk) and 4 genes from the Non-Metastasis group (Low risk)
which totaled up to an 11 gene signature.
E2F had multiple probes and thus their functional properties were considered. A few subsets of
the 11 hallmarks with the help of PubMed were considered to identify gene signatures.
E2F1, E2F2, and E2F3 were a family with functional similarities and E2F3 had the least
significance among them. So it was ignored. Similarly E2F4 and E2F5 were another family with
functional similarities and E2F5 is not as significant as E2F4. So it was ignored.
Thus E2F1, E2F2, and E2F4 were only included with the. remaining 6 hallmarks to make a set of
9 hallmarks to find another signature. The genes that had interactions with all the 9 hallmarks
were picked from both the Metastasis group (High risk) and the Non-Metastasis group (Low
risk). There were 13 genes from the Metastasis group (High risk) and 8 genes from the NonMetastasis group (Low risk) which totaled to a 21 gene signature.
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Since E2F1 and E2F2 were a part of the same family, they had similar functionality and so they
were considered one at a time to find more gene signatures.
When E2F1 and E2F4 were considered along with the remaining 6 hallmarks, there were a total
of 8 hallmarks. All the genes that had interactions with the 8 hallmarks were picked from both
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 18 genes
from the Metastasis group (High risk) and 13 genes from the Non-Metastasis group (Low risk)
which totaled to a 31 gene signature.
When E2F2 and E2F4 were considered along with the remaining 6 hallmarks, there were a total
of 8 hallmarks. All the genes that had interactions with the 8 hallmarks were picked from both
the Metastasis group (High risk) and the Non-Metastasis group (Low risk). There were 32 genes
from the Metastasis group (High risk) and 19 genes from the Non-Metastasis group (Low risk)
which totaled to a 51 gene signature. But there was one gene which was common to both the
groups and thus the signature size becomes 50.
The number of genes identified from each group using different sets of hallmarks is shown in the
Table 3-1 below.
Table 3-1: Number of genes identified to have interactions with major cancer hallmarks in each prognosis
group in each gene signature

11 gene signature
21gene signature
31 gene signature
50 gene signature

genes from poor prognosis
7
13
18
32
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genes from good prognosis
4
8
13
19

Hence 4 signatures were discovered where each one had 11 genes, 21 genes, 31 genes, and 50
genes which are shown in Table 3-2 below. The 50 gene signature has a gene FLJ13059 that was
extracted from both groups.
It can be seen that the 11 gene signature is a subset of all the remaining 3 signatures (21 gene, 31
gene, and 50 gene signatures) and the 21 gene signature is a subset of the remaining 2 signatures
(31 gene and 50 gene signatures). This was because the set of hallmarks used for identifying the
31 gene signature and the 50 gene signature were subsets of the hallmarks used for identifying
the other 2 signatures (11 gene and 21 gene signatures).
But the 31 gene signature and the 50 gene signature had a few unique genes each. Other than the
21 genes in common, they have just one more gene (ESM1) common to both the signatures.
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Table 3-2: All signatures obtained using different combinations of Hallmarks
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

50‐GENE SIGNATURE
ACTL6B
ADAM3B
FABP7
PRR4
RPL27A
SLC22A11
TAC3
215642_at
DEFA5
PALM
SCGB2A2
BCDIN3
GAL3ST1
PCDHB3
PCDHGA3
PRKACA
SAMD4B
ACTR8
CAP2
CDKN2B
TMEM135
217363_x_at
BRD2
C9
COG5
DDB1
DKFZP586P0123
ESM1
FLJ13059
GABRA1
HSPA2
KRT81
MUC8
PEX5L
PPP1R2P9
PRKAA1
SUPT6H
TPSD1
TRIM9
VPS35
ATP6V0B
CHD6
DUSP21
ELL
KIAA1446
SCN8A
SLC26A1
SPINK5
STT3A
TSPAN2

31‐GENE SIGNATURE
ACTL6B
ADAM3B
FABP7
PRR4
RPL27A
SLC22A11
TAC3
215642_at
DEFA5
PALM
SCGB2A2
BCDIN3
GAL3ST1
PCDHB3
PCDHGA3
PRKACA
SAMD4B
ACTR8
CAP2
CDKN2B
TMEM135
C1orf68
dJ222E13.2
LOR
SSFA2
TEX11
217470_at
DAG1
ESM1
H2AFB3
TM4SF20

21‐GENE SIGNATURE
ACTL6B
ADAM3B
FABP7
PRR4
RPL27A
SLC22A11
TAC3
215642_at
DEFA5
PALM
SCGB2A2
BCDIN3
GAL3ST1
PCDHB3
PCDHGA3
PRKACA
SAMD4B
ACTR8
CAP2
CDKN2B
TMEM135
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11‐GENE SIGNATURE
ACTL6B
ADAM3B
FABP7
PRR4
RPL27A
SLC22A11
TAC3
215642_at
DEFA5
PALM
SCGB2A2

3.3.

Survival Analysis

To find the most significant signature from the obtained prognostic signatures, survival analysis
was performed on the four signatures. Survival Analysis was done using techniques which
include Time dependant ROC analysis, Random Test, and Cox proportional hazard model. Cox
model uses Kaplan-Meier plots and log-rank tests to identify the best signature.
3.3.1 Time dependant ROC analysis and Random Test
ROC curve stands for Receiver Operating Characteristic curve. It is a plot between the sensitivity
and the (1-specificity) as time is varied. It can also be considered as the plot between the True
Positive Rate and the False Positive Rate. That is it is used to describe the tradeoff between the
hit rates and the false alarm rates. The higher the area under curve (AUC) values, the better the
signature. The AUCs are calculated using R.
In Random test, genes are picked randomly from the entire set of genes. The number of genes
picked must equal the number of genes in the signature that is being validated. The AUC of the
signature genes is compared with the AUC of the picked genes. Similarly, a large number of
randomly picked signatures are compared with the signature that is being validated. The
performance of the identified gene signature must be significant when compared to the other
randomly picked signatures. The lower the p-value from the random test is, the better is the
signature.
In the datasets, when there were duplicate probes for genes, the probe that resulted in the most
significant (least) p-value when fitted in to Cox model was considered the best probe and was
used for time dependant ROC analysis of the entire signature. Thus time dependant ROC
analysis [16] was done on the Training dataset (UM+HLM) and on both the Test datasets (DFCI
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and MSK). The function “coxph” in R was used for the calculation of p-values to find the most
significant probe from duplicate probes.
The Tables 3-3, 3-5, 3-7 show the AUC values over years starting from 1 to 9 and for all the four
identified signatures in training dataset, DFCI test set and MSK test set respectively. The Tables
3-4, 3-6, 3-8 are the p-values of the corresponding signature obtained when compared to the
randomly picked signatures from random test for training dataset, DFCI test set and MSK test set
respectively.
Table 3-3: AUC’s of training set (256 samples) obtained when best probes among duplicates were considered

1-year
2-years
3-years
4-years
5-years
6-years
7-years
8-years
9-years

11-gene
0.684292
0.648464
0.661654
0.642624
0.640428
0.64902
0.644137
0.628796
0.618716

21-gene
0.73329
0.683333
0.684145
0.675829
0.687573
0.69424
0.696312
0.68712
0.680933

31-gene
0.777634
0.729109
0.711605
0.704544
0.707053
0.703125
0.711665
0.699266
0.693261

50-gene
0.812282
0.722581
0.730173
0.715059
0.728794
0.749081
0.749984
0.743927
0.744874

Table 3-4: p-values from Random test of training set (256 samples) obtained when best probes among
duplicates were considered

3yr random
5yr random

11-gene
0.05
0.32

21-gene
0.11
0.26

31-gene
0.12
0.38

50-gene
0.35
0.78

As per the values shown in the Tables 3-3 above for Training dataset, ROC values were good for
the 50 gene dataset. But according to Table 3-4, the Random test values were bad. The Random
test values from Table 3-4 of the 11 gene and the 31 gene signatures showed better results. So a
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tradeoff between the AUC values and the Random Test values points to the 31 gene signature
which is nearly good in both the validations.
Table 3-5: AUC’s of DFCI test set (82 samples) obtained when best probes among duplicates were considered

1-year
2-years
3-years
4-years
5-years
6-years
7-years
8-years
9-years

11-gene
0.610755
0.660634
0.712601
0.706731
0.719577
0.7225
0.731618
0.728875
0.728875

21-gene
0.682458
0.716742
0.778187
0.802885
0.789021
0.780625
0.77451
0.774468
0.774468

31-gene
0.773368
0.80724
0.847458
0.866071
0.831349
0.839375
0.834559
0.828571
0.828571

50-gene

Error in fitter
Ran out of iterations
and did not converge

Table 3-6: p-values from Random test of DFCI test set (82 samples) obtained when best probe among
duplicates were considered

3 yr random
5yr random

11-gene
0.51
0.49

21-gene
0.45
0.67

31-gene
0.61
0.7

50-gene
Error in fitter
Ran out of iterations

From the Table 3-5 above for DFCI dataset, it was seen that the 50 gene signature had errors to
fit in the model and hence was be ruled out. Since the Random test values from Table 3-6 were
not good for any signature in this dataset, only the AUC values were considered to decide that
the 31 gene signature was better than the other signatures.
Table 3-7: AUC’s of MSK test set (104 samples) obtained when best probes among duplicates were
considered

1-year
2-years
3-years
4-years
5-years
6-years
7-years

11-gene
0.778878
0.720284
0.764359
0.742069
0.72479
0.740196
0.745865

21-gene
0.933993
0.78876
0.828234
0.816092
0.833613
0.841503
0.842275

31-gene
0.980198
0.861757
0.880837
0.848736
0.85
0.851307
0.84994
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50-gene

Error in fitter
Ran out of iterations
and did not converge

8-years
9-years

0.745865
0.745865

0.842275
0.842275

0.84994
0.84994

Table 3-8: p-values from Random test of MSK test set (104 samples) obtained when best probes among
duplicates were considered

3yr random
5yr random

11-gene
0.23
0.35

21-gene
0.19
0.08

31-gene
0.23
0.32

50-gene
Error in fitter
Ran out of iterations

From the values from the Table 3-7 above for MSK dataset, it was seen that the AUC values
show in favor of the 31 gene signature where as the Random test values from Table 3-8 were in
favor of the 21 gene signature.
Thus considering all the three datasets, Time dependant ROC values and Random test together
were more in favor of the 31 gene signature over the other signatures.
3.3.2 Cox proportional hazards model on 11, 21 and 31 Gene Signatures
For the COX modeling, the training dataset is first fit in to the Cox model and then the cutoff
values obtained by the fitting are applied on the test datasets. Three different cutoffs from
training dataset were used which are mean, median and the nearest point.
Mean or Median as cutoff:
The means/medians of the samples of the training dataset were calculated and were applied as
the cutoffs for the test datasets. Kaplan Meier plots were plotted to see if the stratification was
significant. Only three signatures (11-genes, 21-genes and 31-genes) were considered for
evaluation in Cox model. The fourth signature was ignored as it gave errors in the previous
models. The results are shown in Tables 3-9, 3-10 and 3-11 for 11-gene, 21-gene, and 31-gene
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signaturees respectiveely. The Kapplan Meier plots
p
were not
n displayedd for mean/m
median as cuutoff,
as they were
w better fo
or the nearesst point cutofff which willl be discusseed below.
Nearest point as cuttoff:

Figu
ure 3-4: KM pllot of Trainingg data with neearest
point cutoff for 311 genes

Figure 3-33: Finding Nea
arest point as cutoff for
Training data
d
for 31 gen
nes

In this prrocess, the trraining datasset for each signature is fit in the Coox model forr the predictt time
equaling 3 years. Th
he time deppendant ROC
C curve is plotted.
p
Thenn the cutofff point has to
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T choose th
he cutoff pooint, the disttance from thhe point sennsitivity=1 too each and every
e
chosen. To
point on the time dep
pendant RO
OC curve plootted before is calculatedd. The cutofff point wouuld be
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whosee distance is the minimuum. In other words, it iss the point on
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none othher than the point
curve neearest to thee left top corner
c
of thhe plot. Thee point wouuld always be the poinnt of
intersectiion of the tim
me dependannt ROC curvve and the diiagonal (not passing throough origin)). The
plot is shhown in Figu
ure 3-3. Kapplan Meier plots
p
are draw
wn for the 31 gene signaature to see if the
stratificattion of the data
d
was siggnificant or not as show
wn in Figuree 3-4. Since the stratificcation
from KM
M plot was very
v
good annd the log-raank p-value of the datasset was veryy significantt, this
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cutoff point from training set was used to fit the test datasets in the Cox model.Kaplan Meier
plots of the outputs were drawn as shown in Figure 3-5 and Figure 3-6.

Figure 3-5: KM plot of DFCI data with nearest
point cutoff of training data for 31 gene signature

Figure 3-6: KM plot of MSK data with nearest
point cutoff of training data for 31 gene signature

Table 3-9: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test
datasets for 11-gene signature
train cutoff

11-gene signature

train output

MSK test output

DFCI test output

median

Train p-value
0.02989034
Train cutoff
-1.521898

Test p-value
0.08099651
Test cutoff
-1.521898

Test p-value
0.2264746
Test cutoff
-1.521898

mean

Train p-value
0.007076216
Train cutoff
-1.502247

Test p-value
0.03688842
Test cutoff
-1.502247

Test p-value
0.109008
Test cutoff
-1.502247

nearest point

Train p-value
0.007076216
Train cutoff
-1.501426

Test p-value
0.03688842
Test cutoff
-1.501426

Test p-value
0.109008
Test cutoff
-1.501426
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From the Table 3-9 above, it can be seen that the log-rank p-values for 11 gene signature for
MSK dataset were significant but they were not significant for the DFCI dataset for any kind of
cutoff values.
Table 3-10: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test
datasets for 21-gene signature
train cutoff
median

21-gene signature

mean

nearest point

train output
Train p-value
1.86E-05
Train cutoff
-0.7944426

MSK test output
Test p-value
3.99E-05
Test cutoff
-0.7944426

DFCI test output
Test p-value
0.04601307
Test cutoff
-0.7944426

Train p-value
3.51E-05
Train cutoff
-0.8304135

Test p-value
5.57E-05
Test cutoff
-0.8304135

Test p-value
0.06825427
Test cutoff
-0.8304135

Train p-value
1.26E-07
Train cutoff
-0.63574

Test p-value
1.58E-07
Test cutoff
-0.63574

Test p-value
0.01306106
Test cutoff
-0.63574

From the Table 3-10 above, it can be seen that the log-rank p-values for 21 gene signature were
significant, except when the mean was used as a cutoff for DFCI dataset.
Table 3-11: Cox model outputs for various cutoffs of training dataset applied on both DFCI and MSK test
datasets for 31-gene signature
train cutoff

median

31-gene signature

mean

nearest point

train output
Train p-value
1.35E-08
Train cutoff
0.1062929

MSK test output
Test p-value
4.59E-05
Test cutoff
0.1062929

DFCI test output
Test p-value
0.000148722
Test cutoff
0.1062929

Train p-value
1.16E-07
Train cutoff
0.1238266

Test p-value
2.13E-05
Test cutoff
0.1238266

Test p-value
0.000607811
Test cutoff
0.1238266

Train p-value
1.97E-08
Train cutoff
0.1784121

Test p-value
2.13E-05
Test cutoff
0.1784121

Test p-value
0.000124558
Test cutoff
0.1784121
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From the Table 3-11 above, it can be seen that the log-rank p-values for 31 gene signature were
very significant in all the datasets.
Since all the above methods showed good results for 31 gene signature, it was considered to be
further validated. Though the 21 gene signature had almost good results, 31 gene signature was
considered as it included all the 21 genes from the 21 gene signature.
Since 31 gene signature performed well in the above validation techniques, we tried to evaluate
the performance of just the Stage I patients predicted from the above model.
There were 157 patients in the Training dataset who belonged to Stage I and among them 83
patients were predicted as Good Prognosis and 74 patients were predicted as Poor Prognosis. The
log-rank p-value and the KM plot shown in Figures 3-7 below show that Stage I is very
significant in the Training dataset.

Figure 3-7: KM plot of Training data for Stage I patients

There were 56 patients in DFCI dataset who belonged to Stage I and among them 24 patients
were predicted as Good Prognosis and 32 patients were predicted as Poor Prognosis. There were
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63 patients in MSK dataset who belonged to Stage I and among them 41 patients were predicted
as Good Prognosis and 22 patients were predicted as Poor Prognosis.
Thus it can be seen from the Figures 3-8 and 3-9 below that the stratification for Stage I patients
was very significant and that the log-rank p-values were very significant.

Figure 3-8: KM plot of DFCI data for Stage I
patients

Figure 3-9: KM plot of MSK data for Stage I
patients

Then the Stage I was further split in to Stage IA and Stage IB patients and the same analysis was
performed.
There were 76 patients in the training dataset (UM+HLM) who belonged to Stage IA and among
them 48 patients were predicted as Good Prognosis and 28 patients were predicted as Poor
Prognosis. Thus the training dataset (UM+HLM) was significant for Stage IA group according to
the log-rank p-value and KM plot as shown in Figure 3-10 below.
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Figure 3-10: KM plot of Training data for Stage IA patients

There were 11 patients in DFCI dataset who belonged to Stage IA and among them 5 patients
were predicted as Good Prognosis and 6 patients were predicted as Poor Prognosis. There were
27 patients in MSK dataset who belonged to Stage IA and among them 18 patients were
predicted as Good Prognosis and 9 patients were predicted as Poor Prognosis.
According to the KM plots and log-rank p-values shown in Figures 3-11 and 3-12, Stage IA of
the Test sets (DFCI and MSK) was not as significant as Stage I, which might be because of the
fewer number of patients belonging to Stage IA in the analysis.
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Figure 3-11: KM plot of DFCI data for Stage IA
patients

Figure 3-12: KM plot of MSK data for Stage IA
patients

There were 81 patients in the training dataset (UM+HLM) who belonged to Stage IB and among
them 35 patients were predicted as Good Prognosis and 46 patients were predicted as Poor
Prognosis as shown in the KM plot in Figure 3-13 below.

Figure 3-13: KM plot of Training data for Stage IB patients

There were 45 patients in DFCI dataset who belonged to Stage IB and among them 19 patients
were predicted as Good Prognosis and 26 patients were predicted as Poor Prognosis. There were
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36 patients in MSK dataset who belonged to Stage IB and among them 23 patients were
predicted as Good Prognosis and 13 patients were predicted as Poor Prognosis.
Thus Stage IB in DFCI and MSK datasets was significant from the log-rank p-values and KM
plots in the Figures 3-14 and 3-15 shown below.

Figure 3-14: KM plot of DFCI data for Stage IB
patients

3.4.

Figure 3-15: KM plot of MSK data for Stage IB
patients

Summary

This chapter provided a flow chart of the methodology used and discussed how the gene
signatures were identified using implication networks. The details of the datasets used were
mentioned and all the procedures used and the results obtained by the methodology were also
summarized. The major cancer hallmarks which were used to identify signatures were described
and all the gene signatures identified were given. Survival analysis results were provided for all
the datasets. Thus the 31 gene signature was considered to be the most significant from all the
analysis done and it will be considered for further evaluation.
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Chapter 4

4 Prognostic Validation, Clinical Evaluation & Topological Validation
4.1

Introduction

In the earlier chapter, details were provided on the identification of gene signatures. This chapter
discusses about the validation techniques that were used and all the processing that was done on
the datasets. Details about the gene signature were provided. Prognostic validation performed
done using techniques like Concordance probability estimates and Gene set enrichment analysis.
Clinical evaluation was conducted using Multivariate COX proportional hazards model.
Topological validation was done by comparing the interactions from implication networks with
interactions from Bayesian networks built using Tetrad IV. Various web based tools were also
used to confirm the presence and the significance of the interactions from implication networks.
All the results that were obtained from Prognostic validation, Clinical evaluation, and
Topological validation are provided.

4.2

Gene Signature Details and Differentially Expressed genes

Since the 31 gene signature was considered to be the most prognostic signature, the details of the
31 genes were provided. The details include the chromosome locations, molecular functions and
classifications that have been confirmed by Dr. Yong Qian from The National Institute for
Occupational Safety and Health (NIOSH). These details are shown in the Table 4-1 below.
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Table 4-1: Details of the 31 gene signature that have been confirmed by Dr. Yong Qian from NIOSH
Name

Chromosome
location

Unknown
Unknown
ACTL6B

PROBESET ID
(of the best
probe)
215642_at
217470_at
206014_at

ACTR8
ADAM3B
BCDIN3

218658_s_at
217237_at
219798_s_at

3
16q12.1
7q22.1

C1orf68
CAP2
CDKN2B
DAG1

217087_at
212554_at
207530_s_at
205417_s_at

1q21.3
6p22.3
9p21
3p21

DEFA5
dJ222E13.2
ESM1

207529_at
214828_s_at
208394_x_at

8pter‐p21
22q13.2
5q11.2

FABP7

216192_at

6q22‐q23

GAL3ST1
H2AFB3
LOR

205670_at
214412_at
207720_at

22q12.2
Xq28
1q21

PALM
PCDHB3

203859_s_at
221410_x_at

19p13.3
5q31

PCDHGA3

209478_at

5q31

PRKACA
PRR4
RPL27A
SAMD4B
SCGB2A2
SLC22A11

216234_s_at
204919_at
203034_s_at
220457_at
206378_at
220100_at

19p13.1
12p13
11p15
19q13.2
11q13
11q13.1

SSFA2
TAC3
TEX11

202506_at
219992_at
221259_s_at

2q31.3
12q13‐q21
Xq13.1

TM4SF20
TMEM135

220639_at
222209_s_at

2q36.3
11q14.2

10q23.33
4q35.2
7q22

Molecular function

Vesicular transport, spindle orientation,
nuclear migration and chromatin
remodeling

Classification

Structure

Structure
S‐adenosyl‐L‐methionine‐dependent
methyltransferase

Metabolism

Cell growth regulator
Link the cytoskeleton to the
extracellular matrix
Host defense

Oncogene
Structure

Lung endothelial cell‐leukocyte
interactions
Fatty acid uptake, transport, and
metabolism
Sulfotransferase activity
A protein component of histone
A major protein component of the
cornified cell envelope
control of cell shape
Establishment and maintenance of
specific neuronal connections in the
brain
Establishment and maintenance of
specific neuronal connections in the
brain
Protein kinase
Protection in eye
A component of ribosome

Signaling transduction

Mediates saturable uptake of estrone
sulfate, dehydroepiandrosterone
sulfate and related compounds

Metabolism

Vasodilators and secretagogues

Signaling transduction
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Immunity

Metabolism
Metabolism
Structure
Structure
Structure
Structure

Structure

Signaling transduction
Immunity
Metabolism

To find the differentially expressed genes from the 31 gene signature, T-tests and fold changes
were calculated. To perform the Fold change analyses, data should be distributed normally. Since
the data we have been using is not normally distributed, we log transform the data to change it to
the required form. The histograms of a few genes over all the samples and histograms of a few
samples over all the genes were plotted as shown below in the Figures 4-1 and 4-2.

Figure 4-1: Histograms for 4 genes over all the 442 samples of data showing that the log transformed data is
less skewed than data which was not log transformed

Figure 4-2: Histograms for 4 samples, each from one dataset over all the 22215 genes of data showing that the
log transformed data is less skewed than data which was not log transformed
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To find the differentially expressed genes, T-tests and fold changes analyses were performed.
Their results for the 31 genes are shown below in Table 4-2 and Table 4-3. The data for all the
442 samples (UM+HLM+DFCI+MSK) was considered together. T-tests for the 31 genes with
respect to the different predictive factors such as Stage, Tumor Differentiation and Lymph node
metastases are performed. The genes that were significant in T-test (≤ 0.05) are shown with a star
in the plots shown for fold changes further below.
There were three stages (1, 2 and 3) and calculations were conducted with respect to stage 1
samples. For analysis with Stage, T-tests for Stage 2 to Stage 1 had four significant genes and Ttests for Stage 3 to Stage 1 also had four significant genes. They are shown with a star in the
Figure 4-3 below.
There were three kinds of tumor differentiation (well, poorly and moderate differentiated) and
the calculations were performed with respect to well differentiated samples. For analysis with
Tumor Differentiation, T-tests for Moderate differentiation to Well differentiation had six
significant genes and T-tests for Poor Differentiation to Well differentiation had eight significant
genes. They are shown with a star in the Figure 4-4 below.
There were two kinds of lymph node metastases (LN- and LN+) where calculation was done
with respect to LN- samples. For analysis with Lymph node metastases, T-tests for lymph node
positive to lymph node negative had no significant genes. All the results obtained for T-tests are
shown below in Table 4-2.
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Table 4-2: T-test outputs for different predictors such as Stage (Stage-2 to Stage-1 and Stage-3 to Stage-1),
Tumor differentiation (Moderate to Well and Poor to Well) and Lymph node metastases (LN+ to LN-)
outputs for all the 31 genes in the signature

Gene Symbols

215642_at
217470_at
ACTL6B
ACTR8
ADAM3B
BCDIN3
C1orf68
CAP2
CDKN2B
DAG1
DEFA5
dJ222E13.2
ESM1
FABP7
GAL3ST1
H2AFB3
LOR
PALM
PCDHB3
PCDHGA3
PRKACA
PRR4
RPL27A
SAMD4B
SCGB2A2
SLC22A11
SSFA2
TAC3
TEX11
TM4SF20
TMEM135

T‐test for stage
2 to 1

T‐test for stage
3 to 1

0.441814
0.655542
0.727608
0.033593
0.938388
0.858558
0.022491
0.768851
0.446325
0.542864
0.259804
0.595055
0.039148
0.838281
0.727634
0.322762
0.469576
0.267144
0.652335
0.354072
0.16995
0.765668
0.553478
0.877808
0.242397
0.34981
0.024944
0.258139
0.164771
0.858663
0.618155

0.145264
0.338437
0.607288
0.750247
0.068125
0.223081
0.700184
0.457084
0.945302
0.775556
0.189907
0.729298
0.280311
0.818263
0.01859
0.528597
0.575702
0.685552
0.085702
0.105162
0.224605
0.02991
0.011909
0.295199
0.298675
0.770405
0.051833
0.087507
0.161557
0.80129
0.003059
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T‐test for
Tumor
Differentiation
Moderate to
Well
0.857738
0.661369
0.768965
0.551963
0.013012
0.289013
0.169695
0.571463
0.264274
0.97073
0.160888
0.15501
0.000309
0.713371
0.039144
0.743628
0.987738
0.825739
0.029541
0.32659
0.263827
0.194364
0.079101
0.405373
0.94019
0.930257
0.366235
0.903948
0.006716
0.654298
0.00016

T‐test for
Tumor
Differentiation
Poor to Well
0.738474
0.131298
0.173359
0.856646
0.000868
0.802365
0.012192
0.000115
0.894857
0.350751
0.180041
0.765353
0.000389
0.193622
0.002981
0.448308
0.124489
0.884183
0.067242
0.93396
0.023981
0.109536
0.962865
0.134323
0.769274
0.986529
0.005074
0.249307
0.228346
0.818728
0.039461

T‐test for
Lymph node
metastases
LN+ to LN‐
0.322506
0.393442
0.864637
0.055846
0.288685
0.648078
0.193197
0.96312
0.307397
0.855356
0.729967
0.262961
0.050772
0.929565
0.57002
0.514133
0.998675
0.557783
0.603537
0.470739
0.844798
0.742261
0.378543
0.935369
0.493917
0.657845
0.330087
0.743349
0.695372
0.993537
0.820871

Fold Changes for the 31 genes with respect to the different predictive factors such as Stage,
Tumor Differentiation and Lymph node metastases are shown below in Figures 4-3, 4-4, and 4-5
respectively. The genes that have fold changes ≥2 are considered to be upregulated and the genes
that have fold changes ≤0.5 are considered to be down regulated. There were no genes that were
upregulated or down regulated according to Fold changes.
There were three stages (1, 2 and 3) and fold change calculations were conducted with respect to
stage 1 samples which are shown in Figure 4-3. There were three kinds of tumor differentiation
(well, poorly and moderate differentiated) and the calculations were performed with respect to
well differentiated samples which are shown in Figure 4-4. There were two kinds of lymph node
metastases (LN- and LN+) where calculation was done with respect to LN- samples as shown in
Figure 4-5. Error bars showing the 95% confidence intervals are also shown in the figures.
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Table 4-3: Fold changes for different predictors such as Stage (Stage-2 to Stage-1 and Stage-3 to Stage-1),
Tumor differentiation (Moderate to Well and Poor to Well) and Lymph node metastases (LN+ to LN-)
outputs for all the 31 genes in the signature

Gene Symbols

215642_at
217470_at
ACTL6B
ACTR8
ADAM3B
BCDIN3
C1orf68
CAP2
CDKN2B
DAG1
DEFA5
dJ222E13.2
ESM1
FABP7
GAL3ST1
H2AFB3
LOR
PALM
PCDHB3
PCDHGA3
PRKACA
PRR4
RPL27A
SAMD4B
SCGB2A2
SLC22A11
SSFA2
TAC3
TEX11
TM4SF20
TMEM135

Fold Change
for stage 2 to 1
= ∆2/1

Fold Change
for stage 3 to 1
= ∆3/1

1.024592
0.867161
0.559918
0.378939
0.559942
4.87E‐05
0.023504
0.369338
0.260977
0.000011
6.41E‐19
0.030751
0.000932
6.18482
0.066054
0.473328
0.888696
0.237886
0.028522
0.820507
0.061531
2.905829
1.21E‐82
0.500379
0.95827
0.759165
24945.98
5.948372
0.093164
2.79735
0.001094

0.864067
1.641676
1.620453
90.51783
6.168879
6.66E+12
317.101
72610.67
2.634748
9.95E+23
282.4736
230.7319
254493.4
1673.235
228.7593
4.360512
3.77847
7.77E+08
450103.8
4.22E+18
131.563
1447.149
3.3E+171
7.762561
1.18309
1.032998
2.12E+16
2663.06
233.0746
14.56566
118.9389
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Fold Change
for Tumor
Differentiation
Moderate to
Well =
∆Moderate/W
ell
0.96636
1.585661
1.347857
42.39918
2.771941
84896277
51.31794
58115.3
2.371027
5.51E+18
135.1423
13.75698
9091.178
0.253757
19.25724
7.784657
1.710162
1544293
150.0798
502.1335
18.31498
143.6872
2.6E+124
0.908299
0.922625
2.002644
5.86E+24
37.05733
64.09065
2217.304
0.02566

Fold Change
for Tumor
Differentiation
Poor to Well =
∆Poor/Well
1.168628
0.622946
0.609641
0.113063
1.491585
2.63E‐09
0.033108
37.67143
0.473173
2.51E‐09
6.94E‐11
0.023975
0.023702
0.017357
2.281099
0.856106
0.877704
0.000466
3.77E‐05
1.06E‐11
0.017633
0.054177
2.66E‐58
0.304523
0.512091
0.775557
1.584037
0.0004
0.249336
408.6983
2.61E‐12

Fold Change
for Lymph
node
metastases
LN+ to LN‐ =
∆LN+/LN‐
1.047483
0.893683
0.722991
0.236895
0.854981
0.000392
0.141262
0.757832
0.43117
2.44E‐05
3.8E‐13
0.032192
0.034733
4.768529
0.28678
0.494805
1.01584
0.101454
0.036493
0.207464
0.112883
2.557132
1.99E‐69
1.188885
0.908788
0.717989
0.000148
3.777423
0.221878
2.20726
5.41E‐05

Figure 4-3: Fold changes of the 31 genes for Stage, where blue color bars represent fold change of stage 2
w.r.t. stage 1 and red color bars represent fold change of stage 3 w.r.t. stage 1 and genes with stars on the top
represent the significant genes from T-test with p≤0.05.

Figure 4-4: Fold changes of the 31 genes for Tumor Differentiation, where blue color bars represent fold
change of Moderate differentiation w.r.t. Well differentiation and red color bars represent fold change of
Poor differentiation w.r.t. Well differentiation and genes with stars on the top represent the significant genes
from T-test with p≤0.05.
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Figure 4-5: Fold changes of the 31 genes for Lymph node metastases, where blue color bars represent fold
change of lymph node positive w.r.t. lymph node negative.

4.3

Prognostic Validation

Prognostic Validation is done using metrics such as Overall Accuracy, Concordance Probability
Estimate (CPE), and Gene Set Enrichment Analysis (GSEA). Our model is also validated using
other methods in Weka. Now only the 31 gene signature is considered for validation.
4.3.1 Overall Accuracy:
Training data:
Overall Accuracy of the Training data for 31 gene signature was calculated with 3 years as a
cutoff. Poor prognosis corresponds to samples that were dead by the end of the cut off period (in
actual data) or were predicted as high risk through the model (in predicted data). Similarly, good
prognosis corresponds to the samples that had their status to be living by the end of cutoff period
(in actual data) or were predicted as low risk through the model (in predicted data). The
contingency table was formed from the comparison of actual data with the predicted data. The 9
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censored cases were ignored. There were 67 cases in Training data which belonged to Poor
prognosis in both actual data as well as the predicted data which constituted the True Positives.
Similarly there were 88 cases which belonged to Good prognosis in both actual and predicted
data which constituted the True Negatives. Similarly False Positives and False Negatives were
determined for the Training data which are shown below in the Table 4-4 along with the
sensitivity, specificity and overall accuracy. The contingency table for the actual data versus the
predicted data is shown below.

Table 4-4: Sensitivity, Specificity and Overall Accuracy of Training data calculated from contingency table
Training

Actual data

Predicted data

Poor prognosis

95

133

Good prognosis

152

123

Sensitivity
TP / (TP + FN)
= 0.705263

Specificity
TN / (FP + TN)
= 0.578947

Overall Accuracy
(TP+TN)/(TP+FP+FN+TN)
=0.62753

DFCI data:
Overall Accuracy of the DFCI data for 31 gene signature was calculated with 3 years as a cutoff.
Poor prognosis corresponds to samples that were dead by the end of the cut off period (in actual
data) or were predicted as high risk through the model (in predicted data). Similarly, good
prognosis corresponds to the samples that had their status to be living by the end of cutoff period
(in actual data) or were predicted as low risk through the model (in predicted data). The
contingency table was formed from the comparison of actual data with the predicted data. The 5
censored cases were ignored. There were 19 cases in Training data which belonged to Poor
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prognosis in both actual data as well as the predicted data which constituted the True Positives.
Similarly there were 26 cases which belonged to Good prognosis in both actual and predicted
data which constituted the True Negatives. Similarly False Positives and False Negatives were
determined for the DFCI data which are shown below in the Table 4-5 along with the sensitivity,
specificity and overall accuracy. The contingency table for the actual data versus the predicted
data is shown below.

Table 4-5: Sensitivity, Specificity and Overall Accuracy of DFCI data calculated from contingency table
DFCI

Actual data

Predicted data

Poor prognosis

22

49

Good prognosis

55

33

Sensitivity
TP / (TP + FN)
= 0.863636

Specificity
TN / (FP + TN)
= 0.472727

Overall Accuracy
(TP+TN)/(TP+FP+FN+TN)
=0.584416

MSK data:
Overall Accuracy of the MSK data for 31 gene signature was calculated with 3 years as a cutoff.
Poor prognosis corresponds to samples that were dead by the end of the cut off period (in actual
data) or were predicted as high risk through the model (in predicted data). Similarly, good
prognosis corresponds to the samples that had their status to be living by the end of cutoff period
(in actual data) or were predicted as low risk through the model (in predicted data). The
contingency table was formed from the comparison of actual data with the predicted data. The 10
censored cases were ignored. There were 19 cases in Training data which belonged to Poor
prognosis in both actual data as well as the predicted data which constituted the True Positives.
Similarly there were 52 cases which belonged to Good prognosis in both actual and predicted
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data which constituted the True Negatives. Similarly False Positives and False Negatives were
determined for the MSK data which are shown below in the Table 4-6 along with the sensitivity,
specificity and overall accuracy. The contingency table for the actual data versus the predicted
data is shown below.

Table 4-6: Sensitivity, Specificity and Overall Accuracy of MSK data calculated from contingency table
MSK
Poor prognosis
Good prognosis

Actual data

Predicted data

23
71

43
61

Sensitivity
TP / (TP + FN)
= 0.826087

Specificity
TN / (FP + TN)
= 0.732394

Overall Accuracy
(TP+TN)/(TP+FP+FN+TN)
=0.755319

4.3.2 Concordance Probability Estimate (CPE)
CPE [29] was calculated for the 31 gene signature using the function “phcpe” from R for both
the test datasets DFCI and MSK. The outputs of the function were compared with the model
from Shedden et al [20] as shown in Table 4-7.
Table 4-7: Comparison of 31 gene signature with model from Shedden et al [20] on both the Test datasets
where log-rank p-values, hazard ratios, and confidence intervals were obtained from the CPE package which
use the risk scores of the entire signature as input

DFCI dataset
For model from Shedden et al [20]
For 31 gene signature with Risk Scores
MSK dataset
For model from Shedden et al [20]
For 31 gene signature with Risk Scores

Hazard ratio with 95% CI
Log‐rank p‐value
CPE
1.83 [1.24, 2.70]
0.002
0.63
2.68 (1.88, 3.82]
5.30E‐08
0.71
Hazard ratio with 95% CI
Log‐rank p‐value
CPE
1.76 [1.20, 2.60]
0.003
0.62
3.31 [2.11, 5.2]
2.10E‐07
0.70

The hazard ratios for both the test datasets were higher for the 31 gene signature which shows
that the signature has strong capability of estimating the risk. The hazard ratios and the 95%
95

confidence intervals are shown by error bars in the Figure 4-6. The log-rank p-values of the test
datasets are much lower for the 31 gene signature when compared to the results from the model
from Shedden et al [20] as shown in Figure 4-7 which shows that they are highly significant. The
CPE values are supposed to be higher than 0.5 and as high as possible. Figure 4-8 shows that the
31 gene signature had much higher CPE values than the model from Shedden et al [20]. This
proves that the 31 gene signature has better performance in terms of CPE, hazard ratios, and logrank p-values when compared to the model from Shedden et al [20].

Figure 4-6: Hazard ratios and 95% Confidence
Intervals (obtained from the CPE package which
use the risk scores of the entire signature as input)
shown along with error bars for 31gene signature
and the model from Shedden et al.

Figure 4-7: Comparison of p-values (obtained
from the CPE package which use the risk scores of
the entire signature as input) for 31 gene signature
and model from Shedden et al. on a logarithmic
scale

96

Figure 4-8 : Concordance Probability Estimates compared between 31 gene signature and the model from
Shedden et al.

4.3.3 Gene Set Enrichment Analysis(GSEA)
To run GSEA [30], gene expression values of all the genes were taken. Since it is better to have
as many samples as possible, the training (UM+HLM) and test datasets (DFCI and MSK) were
combined to form the 442 samples dataset. The samples were then assigned a class and there
were a few censored cases which did not fall in to either of the classes. Hence there were 358
samples after censoring 84 samples. Three files are loaded into GSEA as shown in Figure 4-9:
first one is the expression dataset file which contains the gene expression values of the entire set
of genes; second one is the phenotype labels file which includes the phenotype labels associated
to each sample; third one is the gene sets file which gives the names of genes for one or more
gene sets.
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Figure 4-9: Screenshot for loading data in to GSEA

We used 15 gene sets which included our 31 gene dataset. The remaining 14 gene sets were
extracted from different published papers. The sizes of the datasets used and the sizes that were
identified by GSEA are shown in the Table 4-8 below.
Table 4-8: Different signatures used to compare the performance of the 31 gene signature in GSEA
NAME
POTTI_133G [51]
CHEN_5G [52]
BEER_50G [53]
SHEDDEN_MA [20]
SHEDDEN_MB [20]
SHEDDEN_MC [20]
SHEDDEN_MD [20]
SHEDDEN_MH [20]
BOUTROS_6G [54]
BHATTACHARJEE_150G [55]
RAPONI_50G [56]
LAU_3G [57]
LU_64G [58]
GUO_35G [59]
IMPLICATION_31G

ORIGINAL SIZE
131
5
49
9591
50
23
36
252
6
131
45
3
63
35
29

AFTER RESTRICTING TO DATASET
125
5
44

STATUS

Rejected!
38
22
32
223
6
124
39
3
59
26
25
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Figure 4-10: Screenshot showing the Basic fields in running GSEA

The datasets were collapsed to gene symbols and HG_U133A chip platform was used. 1000
permutations were done on phenotypes as shown in Figure 4-10. Ratio of classes was taken as a
metric for ranking the genes and the real values of the genes were considered as shown in
Figures 4-11 and 4-12.

Figure 4-11: Screenshot showing the Selection of Metric for ranking genes
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Figure 4-12: Screenshot showing the selection of sorting the gene list based on their real values

There were only 14 gene sets as one of the gene set which had more than 500 genes was filtered
out from the analysis. Out of the 14 gene sets, 9 gene sets were enriched in phenotype “Good”.
In other words they were upregulated in Good prognosis as shown in Table 4-9. There were 4
gene sets among these 9 gene sets which were significant at FDR<25% which includes the
31genes dataset. Out of the 14 gene sets, there were 5 gene sets which were enriched in the
phenotype “Poor”. One of them is significantly enriched at FDR<25% as shown in Table 4-10.
Table 4-9: Different signatures Enriched in phenotype “Good”, which include the 31 gene signature
SIGNATURE
INDEX
1
2
3
4
5
6
7
8
9

NAME
SHEDDEN_MD [20]
SHEDDEN_MC[20]
BHATTACHARJEE_150G [55]
IMPLICATION_31G
GUO_35G [59]
RAPONI_50G [56]
CHEN_5G [52]
SHEDDEN_MB [20]
POTTI_133G [51]

SIZE
32
22
124
25
26
39
5
38
125

ES
0.597466
0.558553
0.2782
0.992265
0.228604
0.221071
0.435005
0.172793
0.069968

NES
2.385339
2.172679
1.553199
1.518779
1.359544
1.393075
1.138269
1.148412
0.786085

NOM p‐
value
0
0
0.044595
0.255459
0.12989
0.156566
0.299257
0.299652
0.694957

FDR q‐value
0
0.006652
0.178669
0.218715
0.28394
0.313299
0.370527
0.41296
0.681874

FWER p‐
value
0
0.013
0.41
0.587
0.845
0.822
0.965
0.962
0.999

Table 4-10: Different signatures Enriched in phenotype “Poor”
SIGNATURE
INDEX
10
11
12
13
14

NAME
SHEDDEN_MH [20]
LU_64G [58]
BEER_50G [53]
BOUTROS_6G [54]
LAU_3G [57]

SIZE
223
59
44
6
3

ES
‐0.51735
‐0.14059
‐0.18432
‐0.2156
‐0.36642

100

NES

NOM p‐
value

‐2.33102
‐1.22657
‐0.99556
‐0.72
‐0.81345

0
0.236994
0.416422
0.826552
0.699589

FDR q‐value
0.00139
0.551122
0.740632
0.799505
0.848576

FWER p‐
value
0.002
0.664
0.897
0.989
0.977

Figure 4-13: Enrichment score plot for the 31 gene
signature picked from implication networks which
shows the Enrichment profile on the top and the
ranked list metric on the bottom

Figure 4-14: Plot showing the Nominal
Enrichment Scores, False Discovery Rates and
Nominal P-values for all the signatures with
Signature index of each signature from Table 4-9
and 4-10. Index 4 represents the 31-gene signature
from implication networks

The Figures 4-13 above shows the Enrichment score plot for the 31 gene signature and Figure 414 shows the comparison plot for nominal p-values and FDR with respect to NES for all the
signatures used, highlighting the 31 gene signature.
4.3.4 Comparison of model with other classification methods using WEKA
The model used to classify the samples in to two groups was compared against randomly picked
classifiers in Weka. Five classifiers were considered which are Random Tree Classifier, Support
Vector Machine (SVM or SMO) classifier, K-nearest neighbors (IBK) classifier, Multilayered
Perceptron classifier (Neural networks), and Bayes Net classifier.
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The actual classification of the groups based on the survival period and status of post operative
survival was compared with the classifications performed by the above mentioned classifiers.
The classification accuracies using nearest point classification in Cox model for implication
networks were calculated from the sensitivity, specificity, and overall accuracy measures
mentioned in the previous sections. Bayesian networks generated from TETRAD IV were also
compared for overall accuracies.
The comparison was performed for 5 year survival on the Training dataset (ULM/HLM). This
dataset had 229 samples after 27 samples were censored. The results are given in the Table 4-11
below. It can be seen that the Cox model had the best classification accuracy. The sensitivity and
specificity values were also calculated along with the overall accuracy. Significance test was
conducted on the accuracies obtained to get the p-values. The significance of all the other models
was calculated with accuracy of the Cox model as reference. If the p-values are small they imply
that the NULL hypothesis (here equal significance of the two compared overall accuracies) is
rejected and that the Alternative hypothesis (significance of larger overall accuracy >
significance of smaller overall accuracy) is strongly supported. Since all the p-values are very
small, it is obvious that the Cox model is highly significant when compared to other models.
These classifications were used to find the Concordance Probability Estimates, log-rank pvalues, hazard ratios, and confidence intervals for each model.
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Table 4-11: Comparison of classification accuracies of various methods from Weka with Cox model on
implication networks on the training dataset using p-values from significance test

Training dataset

correctly
classified
instances

incorrectly
classified
instances

Sensitivity

Specificity

Overall
Accuracy

Z‐
score

P‐
value

121
132
129

108
97
100

56.8%
72.0%
58.4%

48.1%
40.4%
53.8%

52.8%
57.6%
56.3%

2.48
1.45
1.73

0.006
0.073
0.042

132

97

64.0%

50.0%

57.6%

1.45

0.073

120

109

90.4%

6.7%

52.4%

2.56

0.005

133

96

65.6%

49.0%

58.1%

1.34

0.090

147

82

66.4%

61.5%

64.2%

−

−

Random Tree
SMO (or SVM)
IBK
Multilayered
Perceptron(Neural)
Bayes Net
Bayesian Networks
using TETRAD IV
Implication Networks
‐ COX model

The Concordance Probability Estimates, log-rank p-values, hazard ratios, and the confidence
interval calculated from classifications from various models on training dataset (ULM/HLM) are
shown below in Table 4-12. The CPE values are supposed to be higher than 0.5 and the higher
they are, the better is the model. The log-rank p-values of the models must be less than 0.05 and
the lesser they are, the more significant the model is considered to be. The hazard ratios should
be as high as possible and the 95% confidence intervals should not contain 1 in their range. The
Cox model had highly significant results when compared to the other techniques.
Table 4-12: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of
various methods from Weka with Cox model on implication networks on the training dataset

Training dataset
Random Tree
SMO (or SVM)
IBK

log‐rank p‐
values

CPE
0.524456
0.539067
0.55727
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0.535865
0.157513
0.145277

hazard ratios with 95% CI
1.1 [0.809, 1.5]
1.27 [0.909, 1.77]
1.26 [0.923, 1.72]

Multilayered Perceptron(Neural)
Bayes Net
Implication Networks‐COX model

0.57637
0.516962
0.7123937

0.053659
0.816327
3.90E‐08

1.36 [0.992, 1.87]
0.934 [0.53, 1.65]
2.48 [1.79, 3.42]

Since the training dataset had good results, we tried to validate the model on the testing datasets.
The classification from survival time and status was used as actual classification for the DFCI
test dataset. This dataset had 64 samples after 18 samples were censored. The classification
results for DFCI dataset for various classifiers used in Weka are shown below in comparison
with the Cox model in Table 4-13. Bayesian networks generated from TETRAD IV were also
compared for overall accuracies. The sensitivity and specificity values were also calculated along
with the overall accuracy. Significance test was conducted on the accuracies obtained to get the
p-values. The significance of all the other models was calculated with accuracy of the Cox model
as reference. If the p-values are small they imply that the NULL hypothesis (here equal
significance of the two compared overall accuracies) is rejected and that the Alternative
hypothesis (significance of larger overall accuracy > significance of smaller overall accuracy) is
strongly supported. Since all the p-values are very small, it is obvious that the Cox model is
highly significant when compared to other models.
Table 4-13: Comparison of classification accuracies of various methods from Weka with Cox model on
implication networks on the DFCI test dataset using p-values from significance test

DFCI dataset
Random Tree
SMO (or SVM)
IBK
Multilayered
Perceptron (Neural)
Bayes Net

correctly
classified
instances

incorrectly
classified
instances

Sensitivity

Specificity

Overall
Accuracy

Z‐
score

P‐
value

34
27
26

30
37
38

64.3%
92.9%
39.3%

44.4%
2.8%
41.7%

53.1%
42.2%
40.6%

1.44
2.66
2.83

0.075
0.004
0.002

27

37

92.9%

2.8%

42.2%

2.66

0.004

28

36

100.0%

0.0%

43.8%

2.48

0.007
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Bayesian Networks
using TETRAD IV
Implication
Networks‐Cox Model

30

34

60.7%

36.1%

46.9%

2.13

0.017

42

22

92.9%

44.4%

65.6%

−

−

The Concordance Probability Estimates, log-rank p-values, hazard ratios, and the confidence
interval calculated from the model on DFCI dataset are shown below. All the instances in Bayes
Net were classified to the same group (Poor prognosis) and hence calculation of the parameters
was not possible (NA). This is because the calculation of parameters requires at least two
different groups. The CPE values are supposed to be higher than 0.5 and the higher they are, the
better is the model. The log-rank p-values of the models must be less than 0.05 and the lesser
they are, the more significant the model is considered to be. The hazard ratios should be as high
as possible and the 95% confidence intervals should not contain 1 in their range. From the results
shown below in Table 4-14, it can be concluded that Cox model had much significant results
when compared to other techniques.
Table 4-14: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of
various methods from Weka with Cox model on implication networks on the DFCI test dataset

DFCI dataset
Random Tree
SMO (or SVM)
IBK
Multilayered Perceptron(Neural)
Bayes Net
Implication Networks‐COX model

log‐rank p‐
values

CPE
0.543057
0.693209
0.600628
0.693209
NA
0.845703
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0.620414
0.319597
0.230398
0.319597
NA
0.0014

hazard ratios with 95% CI
1.19 [0.597, 2.36]
0.443 [0.106, 1.85]
0.665 [0.34, 1.3]
0.443 [0.106, 1.85]
NA
5.48 [1.93, 15.6]

The classification from survival time and status was used as actual classification for the MSK
test dataset. This dataset had 65 samples after 39 samples were censored. The classification
results for MSK dataset for various classifiers used in Weka are shown below in Table 4-15.
Bayesian networks generated from TETRAD IV were also compared for overall accuracies. The
sensitivity and specificity values were also calculated along with the overall accuracy.
Significance test was conducted on the accuracies obtained to get the p-values. The significance
of all the other models was calculated with accuracy of the Cox model as reference. If the pvalues are small they imply that the NULL hypothesis (here equal significance of the two
compared overall accuracies) is rejected and that the Alternative hypothesis (significance of
larger overall accuracy > significance of smaller overall accuracy) is strongly supported. Since
all the p-values are very small, it is obvious that the Cox model is highly significant when
compared to other models.
Table 4-15: Comparison of classification accuracies of various methods from Weka with Cox model on
implication networks on the MSK test dataset using p-values from significance test

MSK dataset
Random Tree
SMO (or SVM)
IBK
Multilayered
Perceptron(Neural)
Bayes Net
Bayesian Networks
using TETRAD IV
Implication Networks‐
COX model

correctly
classified
instances

incorrectly
classified
instances

Sensitivity

Specificity

Overall
Accuracy

Z‐
score

P‐
value

35
31
26

30
34
39

67.6%
2.9%
29.4%

38.7%
96.8%
51.6%

53.8%
47.7%
40.0%

1.44
2.13
2.99

0.075
0.017
0.001

34

31

100.0%

0.0%

52.3%

1.61

0.054

34

31

100.0%

0.0%

52.3%

1.61

0.054

33

32

58.8%

41.9%

50.8%

1.78

0.037

43

22

64.7%

67.7%

66.2%

−

−
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The log-rank p-values, CPE, hazard ratios, and the confidence interval calculated from the model
on MSK dataset are shown below. All the instances in Multilayered Perceptron and Bayes Net
were classified to the same group (Poor prognosis) and hence calculation of the parameters was
not possible (NA). This is because the calculation of parameters requires at least two different
groups. The CPE values are supposed to be higher than 0.5 and the higher they are, the better is
the model. The log-rank p-values of the models must be less than 0.05 and the lesser they are, the
more significant the model is considered to be. The hazard ratios should be as high as possible
and the 95% confidence intervals should not contain 1 in their range. From the results shown
below in Table 4-16, it can be concluded that Cox model had much significant results when
compared to other techniques.

Table 4-16: Comparison of Concordance Probability Estimates, log-rank p-values (obtained from the CPE
package with risk scores of the entire signature as input), hazard ratios (based on 5-year cutoff) and
confidence intervals (obtained from the CPE package with risk scores of the entire signature as input) of
various methods from Weka with Cox model on implication networks on the MSK test dataset

MSK dataset
Random Tree
SMO (or SVM)
IBK
Multilayered Perceptron(Neural)
Bayes Net
Implication Networks‐COX model

CPE
0.539067
0.538504
0.548117
NA
NA
0.782544

log‐rank p‐
values
0.651084
0.882016
0.565333
NA
NA
0.00019

hazard ratios with 95% CI
1.17 [0.59, 2.32]
1.17 [0.16, 8.53]
0.824 [0.425, 1.6]
NA
NA
3.6 [1.84, 7.05]

Thus all the results above show that the Cox model predicted the outcomes with best
classification accuracies, CPE, log-rank p-values, and hazard ratios with 95% confidence
intervals.
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4.4

Clinical Evaluation

Clinical evaluation was done by comparing various predictive factors such as Age, Gender,
Lymph node metastasis, Tumor size, etc with the risk scores from our model. This is done using
multivariate Cox proportional hazards model.
Multivariate Analysis on Cox proportional hazards model
Multivariate analysis was done using the Cox proportional hazards model to compare the
significance of the risk scores from 31 gene signature with the other pathological factors. For
multivariate analysis, the risk scores of the 31 gene signature obtained in Cox model earlier were
used as a predictor. Mostly used covariates such as Age, Gender, Lymph node Metastasis, and
Tumor size were used with the risk scores of 31 gene predictors as shown in Table 4-17. In this
table, the other predictors were fit in to Cox model without the risk scores and then they were
again fit in to Cox model with the risk scores included. Both the analyses were compared which
showed that the addition of risk scores to other predictors made the significance of other
predictors to decrease and that the risk scores of our model had the most significant p-value.
Table 4-17: Multivariate Cox Proportional Analysis of Age, Gender, Lymph node Metastasis, Tumor size and
Risk Score*

Variable
Analysis without risk score
AGE
GENDER
Lymph node Metastasis
Tumor Size
Analysis with risk score
31 genes Risk Scores
AGE
GENDER
Lymph node Metastasis
Tumor Size

Log‐rank p‐value

Hazard Ratio [95% CI]¥

0.00081
0.059
6.20E‐14
0.0035

1.69 [1.243, 2.3]
0.777 [0.598, 1.01]
2.716 [2.092, 3.53]
1.537 [1.151, 2.05]

2.30E‐14
0.0056
0.12
1.00E‐13
0.084

2.43 [1.933, 3.05]
1.55 [1.136, 2.11]
0.81 [0.623, 1.05]
2.7 [2.081, 3.51]
1.29 [0.966, 1.73]
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*Age was a binary variable (0 for an age less than 60 years and 1 for an age of 60 years or greater); Gender
was a binary variable (0 for Male and 1 for Female); Lymph node Metastasis was a binary variable (0 for N0stage and 1 for all other N-stages and missing values); Tumor size was a binary variable (0 for T0-stage and 1
for all other T-stages and missing values); Risk score was a continuous variable.
¥
CI denotes Confidence interval.

To perform a complete and comprehensive analysis on the pathological factors of Non-Small
Cell Lung Cancer, all the other covariates like Race, Smoking status, and Tumor grade were
added to the above covariates to find the log-rank p-values and Hazard ratios as shown in Table
4-18. Again analyses with and without risk scores was done and it can be seen that 31 gene
predictors are most significant. The smoking status can be ignored as it has a group of unknown
samples which would not allow the correct prediction of the entire group. The descriptions of
each of the variables are given in the legends of the tables.
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Table 4-18: Multivariate Cox Proportional Analysis of Age, Gender, Race, Smoking Status, Lymph node
Metastasis, Tumor size, Tumor grade and Risk Score*

Variable
Analysis without risk score
AGE
GENDER
RACE
Other
White
SMOKING STATUS
Smokers
Unknown
Lymph node Metastasis
Tumor Size
TUMOR GRADE
POORLY DIFFERENTIATED
WELL DIFFERENTIATED
Analysis with risk score
31 genes Risk Scores
AGE
GENDER
RACE
Other
White
SMOKING STATUS
Smokers
Unknown
Lymph node Metastasis
Tumor Size
TUMOR GRADE
POORLY DIFFERENTIATED
WELL DIFFERENTIATED

Log‐rank p‐value

Hazard Ratio [95% CI] ¥

0.00069
0.059

1.705 [1.253, 2.32]
0.763 [0.576, 1.01]

0.76
0.72

0.877 [0.375, 2.05]
1.161 [0.512, 2.63]

0.4
0.25
3.60E‐14
0.0026

1.23 [0.761, 1.99]
1.385 [0.797, 2.41]
2.788 [2.138, 3.64]
1.569 [1.17, 2.1]

0.35
0.38

1.144 [0.865, 1.51]
1.211 [0.788, 1.86]

1.80E‐13
0.0061
0.19

2.403 [1.903, 3.03]
1.544 [1.132, 2.11]
0.827 [0.621, 1.1]

0.56
0.74

0.774 [0.329, 1.82]
0.872 [0.382, 1.99]

0.54
0.3
8.90E‐14
0.074

1.164 [0.719, 1.88]
1.35 [0.769, 2.37]
2.737 [2.1, 3.57]
1.311 [0.975, 1.76]

0.44
0.61

1.117 [0.843, 1.48]
1.116 [0.727, 1.71]

*Age was a binary variable (0 for an age less than 60 years and 1 for an age of 60 years or greater); Gender
was a binary variable (0 for Male and 1 for Female); Race was a binary variable (Other relative to
Black/African American, White relative to Black/African American; Other includes a few Native
Hawaiian/Pacific Islander, Asian and unknown); Smoking status was a binary variable (Smokers relative to
Non-Smokers and Unknown status relative to Non-Smokers); Lymph node Metastasis was a binary variable
(0 for N0-stage and 1 for all other N-stages and missing values); Tumor size was a binary variable (0 for T0stage and 1 for all other T-stages and missing values); Tumor grade was a binary variable (Poorly
differentiated relative to moderately differentiated and Well differentiated relative to moderately
differentiated); Risk score was a continuous variable.
¥
CI denotes Confidence interval.
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4.5

Topological Validation

To derive the biological insight using curated databases, topological validation was performed on
the prognostic signature obtained from prediction logic based implication networks. This
validation also required the comparison of the biological relevance of the interactions present in
the implication network with a currently used network such as Bayesian network. There are
many techniques for structural validation of the gene signature.
In prognostic validation, the best probe was considered based on the minimum p-value after
fitting in to Cox model. But in structural validation, the average of all the duplicate probes was
taken and was used for the analysis. The different structural validation techniques used include
Prodistin, Kegg, NCI pathways, PubMed interactions, Matisse, String 8, Ingenuity Pathway
Analysis, and Pathway Studio. Tetrad IV was used to generate Bayesian networks which were
compared in different aspects with the implication network.
The implication network was built from the 31 genes and the hallmarks used to identify the
signature.
The gene expression data of the 22215 genes was sorted according to their gene symbols. The
averages of the duplicate probes were taken which leaves 13658 unique genes. The 31 genes
along with the hallmarks which were used to get the 31 gene signature were picked. Hence there
were 31 genes plus 8 hallmarks. There were 256 samples in the Training dataset. This data is
split in to 2 files, Metastasis (high risk) and Non-Metastasis (low risk) groups, based on the
number of months they survived and survival status. If the number of months the patients
survived was greater than 60 (5 years), the sample was put in Non-Metastasis group (low risk). If
the number of months the patients survived was less than 60 months and if it was known that the
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patient died, the sample was put in Metastasis group (high risk). If the number of months the
patients survived was less than 60 months and if it was not known whether the patient died, the
sample was censored.
The Metastasis group (high risk) had 125 samples and the Non-Metastasis group (low risk) had
104 samples. The remaining 27 samples were censored as shown in Table 4-19. The data in the
files was converted in to 1’s and 0’s by partitioning based on the mean which was used to
generate the interactions among genes.
Table 4-19: Number of patients in each of the groups in each dataset along with number of censored patients

Training dataset
DFCI dataset
MSK dataset

# patients in high risk
(Metastasis) group
125
28
34

# patients in low risk (Non‐
Metastasis) group
104
36
31

# patients
censored
27
18
39

Interactions between genes were generated using the files which had binary data. There were
1021 interactions from Metastasis group (high risk) and 897 interactions from the NonMetastasis group (low risk) as shown in Table 4-20.
The above steps were repeated for the 31 gene signature in DFCI data set and the MSK data set.
The DFCI dataset had 82 samples. After partitioning, there were 28 samples for Metastasis group
(high risk) and 36 samples for Non-Metastasis group (low risk). There were 18 samples which
were censored as shown in Table 4-19. There were 787 interactions from Metastasis group (high
risk) and 938 interactions from Non-Metastasis group (low risk) as shown in Table 4-20.
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The MSK dataset had 104 samples. After partitioning, there were 34 samples for Metastasis
group (high risk) and 31 samples for Non-Metastasis group (low risk). There were 39 samples
that were censored as shown in Table 4-19. There were 992 interactions from Metastasis group
(high risk) and 996 interactions from Non-Metastasis group (low risk) as shown in Table 4-20.
Table 4-20: Number of interactions between the 31 genes and the 8 hallmarks for various datasets in both the
groups

Low risk (Non‐Metastasis)
Interactions from Training=897
Interactions from DFCI=938
Interactions from MSK=996

High risk (Metastasis)
Interactions from Training=1021
Interactions from DFCI=787
Interactions from MSK=992

Differential components are the interactions that are present in one group (high or low) but not
present in the other group (low or high).
The interactions from the good and poor prognosis of the Training dataset had 235 interactions in
common. So there were 786 interactions from the Metastasis group (high risk) and 662
interactions from the Non-Metastasis group (low risk) that were considered as the differential
components as shown in Table 4-21.
Similarly, the interactions from the good and poor prognosis of the DFCI dataset had 308
interactions in common. So there were 479 interactions from the Metastasis group (high risk) and
630 interactions from the Non-Metastasis group (low risk) that were considered as the
differential components as shown in Table 4-21.
Similarly, the interactions from the good and poor prognosis of the MSK dataset had 359
interactions in common. So there were 633 interactions from the Metastasis group (high risk) and
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637 interactions from the Non-Metastasis group (low risk) that were considered as the
differential components as shown in Table 4-21.
Table 4-21: Number of differential components between both the groups for the 31 genes and the 8 hallmarks
for various datasets

Low risk (Non-Metastasis)
Differential Components from Training=662
Differential Components from DFCI=630
Differential Components from MSK=637

High risk (Metastasis)
Differential Components from Training=786
Differential Components from DFCI=479
Differential Components from MSK=633

After getting the differential components for each dataset, the interactions that were common
among every two datasets and also those interactions that were common among all the three
datasets were found.
Among the Metastasis group (high risk), there were 81 interactions common to the differential
components of the Training dataset and the DFCI dataset. The interactions between the genes are
shown graphically in the Figure 4-15 below. There were 168 interactions common to the
differential components of the Training dataset and the MSK dataset. The interactions between
the genes are shown graphically in the Figure 4-16 below. There were 61 interactions common to
the differential components of the DFCI dataset and the MSK dataset. The interactions between
the genes are shown graphically in the Figure 4-17 below. The genes in yellow color are the
Hallmarks used and the uncolored genes are the regular signature genes. There were 31
interactions that were common to all the three datasets in the Metastasis group (high risk). The
interactions between the genes are shown in the Figure 4-18 below.
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Figure 4-15: Differential Components common to
Train & DFCI datasets in high risk group

Figure 4-16: Differential Components common to
Train & MSK datasets in high risk group

Figure 4-17: Differential Components common to
DFCI & MSK datasets in high risk group

Figure 4-18: Differential Components common to
all 3 datasets in high risk group

Among the Non-Metastasis group (low risk), there were 96 interactions common to the
differential components of the Training dataset and the DFCI dataset. The interactions between
the genes are shown graphically in the Figure 4-19 below. There were 106 interactions common
to the differential components of the Training dataset and the MSK dataset. The interactions
between the genes are shown graphically in the Figure 4-20 below. There were 82 interactions
common to the differential components of the DFCI dataset and the MSK dataset. The
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interactions between the genes are shown graphically in the Figure 4-21 below. There were 27
interactions that were common to all the three datasets in the Non-Metastasis group (low risk).
The interactions between the genes are shown in the Figure 4-22 below.

Figure 4-19: Differential Components common to
Train & DFCI datasets in low risk group

Figure 4-20: Differential Components common to
Train & MSK datasets in low risk group

Figure 4-21: Differential Components common to
DFCI & MSK datasets in low risk group

Figure 4-22: Differential Components common to
all three datasets in low risk group

All these common interactions between the three datasets are shown in the Figure 4-23 below.
This figure also shows the number of genes present in the interactions common to all the three
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datasets in both poor and good prognosis groups. The molecular and cellular functions of these
genes are mentioned which were extracted from Ingenuity Pathway Analysis (IPA)

Figure 4-23: Differential Components common among the three datasets in both the prognosis groups where
good prognosis corresponds to low risk group and poor prognosis corresponds to high risk group and the
major molecular and cellular functions identified from IPA were also shown

4.5.1 PRODISTIN
PRODISTIN is web based software that functionally classifies the genes based on the proteinprotein interactions. It is based on the principle that the more two proteins share common
interactors, the more they are functionally related. It clusters proteins in to functional classes
depending whether they participate in the same cellular process or not. It also predicts function
for unknown genes.
The process started with the selection of species to Homo sapiens. Then the interaction network,
which is a file that includes the total number of interactions and the interactions between the
genes common to Training data and the DFCI data in the Metastasis group were loaded. The
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gene/protein connectivity was put as 1 as it is the minimal connectivity threshold. There were 22
genes/proteins that were classified by the Prodistin Method (by computing Czekanowski-Dice
distance between all possible pairs) from the uploaded network. From the 22 classified genes,
there were 12 genes that were non-annotated based on the Functional class identification. The
tree was drawn grouping the genes of the same functional annotation in to one class where
functional annotations are derived from the GO terms. There were 3 different GO terms which
are shown in the Figure 4-24 below. If there are multiple Gene Ontology terms for a single class,
that class would be represented by a color representing one of those multiple terms. Some classes
may contain other smaller classes.

118

Figure 4-24: Clustering from interactions Common to Train and DFCI Metastasis group from PRODISTIN

The terms primary metabolism and macromolecule metabolism fall in to one class which is give
a class number 1. P-values are shown in Table 4-22. The p-values are not very significant in this
dataset.
Table 4-22: p-values of Gene Ontology terms identified from known classes in Common interactions among
Train and DFCI Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

5

primary metabolism

0.4762

1

5

macromolecule metabolism

0.4762
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The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to Training data and the MSK data in the Metastasis
group were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity
threshold. There were 34 genes/proteins that were classified by the Prodistin Method (by
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network.
From the 34 classified genes, there were 16 genes that were non-annotated based on the
Functional class identification. The tree was drawn grouping the genes of the same functional
annotation in to one class where functional annotations are derived from the GO terms. There
were 10 different GO terms which are shown in the Figure 4-25 below. If there are multiple
Gene Ontology terms for a single class, that class would be represented by a color representing
one of those multiple terms. Some classes may contain other smaller classes.
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Figure 4-25: Clustering from interactions Common to Train and MSK Metastasis group from PRODISTIN

The terms cell communication, protein modification and system development fall into class
number 1, primary metabolism and macromolecule metabolism fall in to class number 2, protein
metabolism and cellular metabolism fall in to class number 3, signal transduction falls in to class
number 4, and morphogenesis falls in to class number 7. P-values are shown in Table 4-23. The
p-values of primary metabolism and macromolecule metabolism are significant.
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Table 4-23: p-values of Gene Ontology terms identified from known classes in Common interactions among
Train and MSK Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

5

cell communication

0.3921

1

5

protein modification

0.2247

1

5

system development

0.2941

2

12

primary metabolism

0.0498

2

12

macromolecule metabolism

0.0498

3

8

protein metabolism

0.3628

3

8

cellular metabolism

0.2639

4

6

signal transduction

0.3620

7

6

morphogenesis

0.3111

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to DFCI data and the MSK data in the Metastasis group
were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity
threshold. There were 21 genes/proteins that were classified by the Prodistin Method (by
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network.
From the 21 classified genes, there were 11 genes that were non-annotated based on the
Functional class identification. The tree was drawn grouping the genes of the same functional
annotation in to one class where functional annotations are derived from the GO terms. There
were no GO terms identified. This is shown in Figure 4-26 below. Hence there are no p-values
identified. If there are multiple Gene Ontology terms for a single class, that class would be
represented by a color representing one of those multiple terms. Some classes may contain other
smaller classes.
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Figure 4-26: Clustering from interactions Common to DFCI and MSK Metastasis group from PRODISTIN

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to Training data and the DFCI data in the NonMetastasis group were loaded. The gene/protein connectivity was put as 1 as it is the minimal
connectivity threshold. There were 27 genes/proteins that were classified by the Prodistin
Method (by computing Czekanowski-Dice distance between all possible pairs) from the
uploaded network. From the 27 classified genes, there were 11 genes that were non-annotated
based on the Functional class identification. The tree was drawn grouping the genes of the same
functional annotation in to one class where functional annotations are derived from the GO
terms. There were 3 different GO terms which are shown in the Figure 4-27 below. If there are
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multiple Gene Ontology terms for a single class, that class would be represented by a color
representing one of those multiple terms. Some classes may contain other smaller classes.

Figure 4-27: Clustering from interactions Common to Train &DFCI Non-Metastasis group from
PRODISTIN

The term regulation of progression through cell cycle falls in to class number 1 and cell
organization and biogenesis falls in to class number 3. P-values are shown in Table 4-24. The pvalues are not very significant in this dataset.
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Table 4-24: p-values of Gene Ontology terms identified from known classes in Common interactions among
Train &DFCI Non-Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

5

regulation of progression through cell cycle

0.2398

3

5

cell organization and biogenesis

0.3916

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to Training data and the MSK data in the NonMetastasis group were loaded. The gene/protein connectivity was put as 1 as it is the minimal
connectivity threshold. There were 31 genes/proteins that were classified by the Prodistin
Method (by computing Czekanowski-Dice distance between all possible pairs) from the
uploaded network. From the 31 classified genes, there were 14 genes that were non-annotated
based on the Functional class identification. The tree was drawn grouping the genes of the same
functional annotation in to one class where functional annotations are derived from the GO
terms. There were 8 different GO terms which are shown in the Figure 4-28 below. If there are
multiple Gene Ontology terms for a single class, that class would be represented by a color
representing one of those multiple terms. Some classes may contain other smaller classes.
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Figure 4-28: Clustering from interactions Common to Train & MSK Non-Metastasis group from
PRODISTIN

The terms primary metabolism, cellular metabolism and biopolymer metabolism fall into class
number 1, morphogenesis, cell organization, and biogenesis fall into class number 2 and protein
modification and cell communication fall into class number 3. P-values are shown in Table 4-25.
The p-values are very significant in this dataset.
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Table 4-25: p-values of Gene Ontology terms identified from known classes in Common interactions among
Train & MSK Non-Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

8

primary metabolism

0.1282

1

8

cellular metabolism

0.2447

1

8

biopolymer metabolism

0.3426

2

6

morphogenesis

0.1573

2

6

cell organization and biogenesis

0.2447

3

5

protein modification

0.2884

3

5

cell communication

0.4038

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to DFCI data and the MSK data in the Non-Metastasis
group were loaded. The gene/protein connectivity was put as 1 as it is the minimal connectivity
threshold. There were 25 genes/proteins that were classified by the Prodistin Method (by
computing Czekanowski-Dice distance between all possible pairs) from the uploaded network.
From the 25 classified genes, there were 10 genes that were non-annotated based on the
Functional class identification. The tree was drawn grouping the genes of the same functional
annotation in to one class where functional annotations are derived from the GO terms. There
were 6 GO terms as shown in the Figure 4-29 below. If there are multiple Gene Ontology terms
for a single class, that class would be represented by a color representing one of those multiple
terms. Some classes may contain other smaller classes.

127

Figure 4-29: Clustering from interactions Common to DFCI & MSK Non-Metastasis group from
PRODISTIN

The terms cellular metabolism and protein metabolism fall into class number 1, intracellular
signaling cascade, cell organization, and biogenesis fall into class number 2, and cell
communication falls into class number 4. P-values are shown below in Table 4-26. The p-values
are not very significant in this dataset.
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Table 4-26: p-values of Gene Ontology terms identified from known classes in Common interactions among
DFCI & MSK Non-Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

6

cellular metabolism

0.3730

1

6

protein metabolism

0.3730

2

6

intracellular signaling cascade

0.3730

2

6

cell organization and biogenesis

0.3730

4

8

cell communication

0.3496

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to all the three datasets (Train data, DFCI data and the
MSK data) in the Metastasis group were loaded. The gene/protein connectivity was put as 1 as it
is the minimal connectivity threshold. There were 14 genes/proteins that were classified by the
Prodistin Method (by computing Czekanowski-Dice distance between all possible pairs) from
the uploaded network. From the 14 classified genes, there were 7 genes that were non-annotated
based on the Functional class identification. The tree was drawn grouping the genes of the same
functional annotation in to one class where functional annotations are derived from the GO
terms. There were 2 GO terms as shown in the Figure 4-30 below. If there are multiple Gene
Ontology terms for a single class, that class would be represented by a color representing one of
those multiple terms. Some classes may contain other smaller classes.
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Figure 4-30: Clustering from interactions Common to 3 datasets Metastasis group from PRODISTIN

The term system development falls into class number 2. P-values are not related as shown in
Table 4-27.
Table 4-27: p-values of Gene Ontology terms identified from known classes in Common interactions of 3
datasets Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

2

8

system development

NR

The interaction network, which is a file that includes the total number of interactions and the
interactions between the genes common to all the three datasets (Train data, DFCI data and the
MSK data) in the Non-Metastasis group were loaded. The gene/protein connectivity was put as 1
as it is the minimal connectivity threshold. There were 18 genes/proteins that were classified by
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the Prodistin Method (by computing Czekanowski-Dice distance between all possible pairs)
from the uploaded network. From the 18 classified genes, there were 8 genes that were nonannotated based on the Functional class identification. The tree was drawn grouping the genes of
the same functional annotation in to one class where functional annotations are derived from the
GO terms. There were 4 GO terms as shown in the Figure 4-31 below. If there are multiple Gene
Ontology terms for a single class, that class would be represented by a color representing one of
those multiple terms. Some classes may contain other smaller classes.

Figure 4-31: Clustering from interactions Common to 3 datasets Non-Metastasis group from PRODISTIN

The term regulation of cell cycle falls in to class number 1, cell communication falls in to class
number 3, and cell organization and biogenesis falls in to class number 4. P-values are shown in
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Table 4-28. The cell communication and cell organization and biogenesis classes were very
significant in this dataset.
Table 4-28: p-values of Gene Ontology terms identified from known classes in Common interactions of 3
datasets Non-Metastasis group from PRODISTIN
Class Num

Number of genes in each class

Gene Ontology Term

P-Value

1

5

regulation of cell cycle

0.1190

3

8

cell communication

0

4

3

cell organization and biogenesis

0.0476

4.5.2 TETRAD IV
Tetrad IV is a software program used for simulating data from causal or statistical models. It is
also used for estimating, testing, predicting and searching for causal or statistical models. It
implements Bayes networks to generate graphical statistical/causal model for categorical data.
The networks were generated using Bayesian Belief networks. The 31 genes signature were
picked from all the three datasets and the data was partitioned in to 2 groups based on the
survival times and status of the patients. The Metastasis group and the Non-Metastasis group
were given as the data inputs to the software. The model used is shown in Figure 4-32 below.
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Figure 4-32: Model used to build Bayesian networks using Tetrad IV which uses PC search, Bayes
parametric model, ML Bayes Estimator, Bayes instantiated model, and Bayes classifier

The Metastasis groups of the datasets were given as data wrappers and PC pattern search was
used on the data. DAG in pattern graph was considered as the output which was given as the
input to the Parametric Model which uses Bayes parametric model. The output of the Bayes PM
and the Data were given as input to the Estimator where ML Bayes Estimator is used. This
output was given to the Bayes instantiated model. The output of the Bayes instantiated model
along with the data is given to the Bayes updater classifier. The networks for Train Metastasis
group as input is shown in Figure 4-33, DFCI Metastasis group as input is shown in Figure 4-34,
and MSK Metastasis group is shown in Figure 4-35.
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135

Figure 4-36: Interactions from 31 genes and the 8 hallmarks in Train Non-Metastasis group using Tetrad IV

Figure 4-37: Interactions from 31 genes and the 8 hallmarks in DFCI Non-Metastasis group using Tetrad IV
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Figure 4-38: Interactions from 31 genes and the 8 hallmarks in MSK Non-Metastasis group using Tetrad IV

It can be seen that the 31 gene signature is connected even when using Bayesian Belief
Networks. It can also be seen from the figures above that the implication networks are more
connected when compared to the Bayesian Belief Networks. All the interactions from the
Bayesian networks were also present in the interactions from implication networks.
4.5.3 KEGG
KEGG stands for Kyoto Encyclopedia for Genes and Genomes. As the name suggests, it is an
encyclopedia (a large set) of genes. It is a database of 19 databases. These databases are
categorized in to systems information (includes 4 databases), genomic information (includes 9
databases), and chemical information (includes 6 databases). The database that was used was the
KEGG PATHWAY database which is in the systems information to find the signal pathways of
the 31 genes in the signature. All the genes are searched and the genes found interacting with the
remaining signature genes and hallmarks were noted. The Figure 4-39 below shows the
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interactions that were derived from KEGG PATHWAY. The genes that are colored are the
Hallmarks and the genes without colors are the signature genes. All the interactions extracted
from KEGG shown below were also confirmed to be a part of the implication networks.

Figure 4-39: Interactions among 31 genes and the 8 hallmarks extracted from KEGG PATHWAY database
and all of them are confirmed with the interactions from implication networks

4.5.4 NCI Pathways
Pathway Interaction Database (PID) is a highly structured database. It is a curated collection of
information about known biomolecular interactions and key cellular processes assembled in to
authoritative human signaling pathways. It includes pathways from various reliable sources such
as NCI-Nature curated data, BioCarta data, and Reactome data. All the signature genes and the
hallmarks were searched in the pathways and those genes found to be interacting with one
another were noted down. The Figure 4-40 below shows the interactions that were derived from
PID. The genes that are colored are the Hallmarks and the genes without colors are the signature
genes. All the interactions extracted from NCI shown below were also confirmed to be a part of
the implication networks.
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Figure 4-40: Interactions among 31 genes and the 8 hallmarks extracted from NCI pathways and all of them
are confirmed with the interactions from implication networks

4.5.5 PubMed interactions
PubMed was developed at the National Library of Medicine (NLM) which was located at the US
National Institutes of Health (NIH). It was developed by National Center for Biotechnology
Information (NCBI). It is a search engine which includes accesses to many databases in the field
of medicine and related disciplines. It also holds the links to an enormous number of citations,
abstracts, journals and full text articles. The signature genes and the hallmarks were searched in
PubMed and their interactors were noted if they were present among the signature genes or the
hallmarks. The Figure 4-41 below shows the interactions between the signature genes and the
Hallmarks. The genes that are colored are the Hallmarks and the genes without colors are the
signature genes. All the interactions extracted from PubMed shown below were also confirmed
to be a part of the implication networks.
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Figure 4-41: Interactions among 31 genes and the 8 hallmarks extracted from PubMed and all of them are
confirmed with the interactions from implication networks

4.5.6 Matisse
Matisse stands for Modular Analysis via Topology of Interactions and Similarity Sets. It is a
software program for detecting the functional modules present in a set of data. It uses an
interaction network which has already been generated from trustworthy sources. It acts as a tool
to identify sets of genes that are highly correlated and also connected sub graphs in networks.
The species was selected as Homo sapiens. An interaction network for human genomes (pre
generated) was loaded. The gene expression file of the Training dataset for the 31 gene signature
along with the hallmarks was loaded and the program was ran which detects the nodes and edges
(6214 and 25086 respectively) of the interaction network and expression patterns and conditions
(39 and 256) of the dataset loaded. New Modules were found using different algorithms like
Matisse and Expression k-means. The minimum seed and module sizes were varied between 1
and 5. Correlation coefficients were found using one of the various methods such as Dot product
(Pearson), Euclidean distance, Spearman correlation, and Partial correlation. The modules
contained many genes which were not present in the 31 gene signature and so they were ignored.
The gene interactions which included the genes from the signature and Hallmarks are shown in
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the Figure 4-42 below. All the interactions extracted from Matisse shown below were also
confirmed to be a part of the implication networks.

Figure 4-42: Interactions among 31 genes and the 8 hallmarks extracted from MATISSE and all of them are
confirmed with the interactions from implication networks

4.5.7 STRING 8
STRING stands for Search Tool for the Retrieval of Interacting Genes/Proteins. It is web based
tool used to extract the protein-protein interactions between the set of genes that were input to it.
It also includes interactions from various other sources such as MINT, HPRD, BIND, DIP, etc.
other than the interactions that were extracted from its algorithm.
The 31 genes along with the 8 hallmarks were input to STRING. It identified all the genes from
its database in various species and generates a list where the most probable species was
highlighted at the top of the list. Once the species was selected, it gave a list of aliases for each of
the genes with the most important one highlighted. Some genes might not be found in its
database. After the required genes were selected, it generated a figure of the network that was
generated using medium confidence of 0.4 as a default value. The evidence view of the network
generated is shown in the Figure 4-43 below. Each color in the interactions corresponds to a
different source as shown in Figure 4-44. All the interactions extracted from STRING shown
below were confirmed to be present in the implication networks.
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Figure 4-45: List of the input genes (among 31 gene signature) that were identified by STRING 8 and were
displayed at the output

4.5.8 Ingenuity Pathway Analysis
When the 31 genes along with the 8 hallmarks were input in to IPA, it generated five networks
that were significant. The networks contained not only the genes from the signature but also
those that that played an important role in the network. The five networks are shown below in the
Figures 4-46 to 4-50.
The first network shown in Figure 4-46 had 33 molecules and is associated with Network
Functions such as Cancer, Cellular Growth and Proliferation, and Hematological Disease. The
second network shown in Figure 4-47 is associated with Network Functions such as Cancer, Cell
Cycle, and Cellular Development. The third network shown in Figure 4-48 is associated with
Network Functions such as Cell Morphology, Cellular Assembly and Organization, and
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Connective Tissue Development and Function. The fourth network shown in Figure 4-49 is
associated with Network Functions such as Infection Mechanism, Cancer, and Hepatic System
Disease. The fifth network shown in Figure 4-50 is associated with Network Functions such as
Infection Mechanism, Gene Expression, and Cancer.
There are a lot of Bio Functions under the Diseases and Disorder, Molecular and Cellular
Functions, Physiological System Development and Function that were found from the signature
which had very significant p-values. There were also Canonical Pathways, Tox lists, and Tox
Functions which were significant.

Figure 4-46: Network 1 generated from IPA

Figure 4-47: Network 2 generated from IPA
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Figure 4-48: Network 3
generated from IPA

Figure 4-49: Network 4
generated from IPA

Figure 4-50: Network 5
generated from IPA

When all the five networks were merged to form a big network, it had two types of connections.
The highlighted interactions between the genes were the inter network connections that did not
exist in the five networks shown above. They were emerged just because of the merging. This
merged network is shown below in Figure 4-51.
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Figure 4-51: Merged network from all the 5 networks shown above where grey connections are the intranetwork connections and orange connections are inter-network connections in IPA

All the interactions involving the 31 genes signature and the 8 hallmarks only were separated.
These interactions were confirmed to be present in the implication network. These interactions
are shown in the Figure 4-52 below. Each node is of different shape and the legend explains the
meaning of each of the shapes. The solid lines represent the direct interactions and the dotted
lines represent the indirect interactions.
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Figure 4-52: Interactions between the 31 genes and the 8 cancer hallmarks extracted from the merged
network of all the 5 networks in IPA shown above where the yellow genes represent the major cancer
hallmarks

4.5.9 Pathway Studio
The 31 genes signature and the 8 hallmarks were input to Pathway Studio. All the genes except
215642_at and 217470_at were found. Hence the signature contained only 29 genes which were
fed into Pathway Studio. It generated a network as shown below in Figure 4-61. There were
numerous interactions in between a pair of genes which indicate that different kinds of
relationships were found between those genes from different sources. All the interactions shown
in the Figure below were confirmed to be present in the implication network.
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Figure 4-53: Interactions between the 31 genes and the 8 hallmarks that were extracted from Pathway studio
where each kind of line represents different kinds of relationships between the genes

4.6

Summary

This chapter provided the results that were obtained from the performed analyses. Thus the
number of interactions of implication networks and Bayesian networks, in different datasets for
the 31 gene signature in each of the groups are concluded below in Table 4-29. It can be seen
that the implication networks were able to detect many more gene/protein interactions when
compared to the Bayesian networks.
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Table 4-29: Comparison of number of interactions from Poor and Good Prognosis of each dataset generated
in Implication Networks and Bayesian Networks (using Tetrad IV)

TRAINING GOOD PROGNOSIS
TRAINING POOR PROGNOSIS
DFCI GOOD PROGNOSIS
DFCI POOR PROGNOSIS
MSK GOOD PROGNOSIS
MSK POOR PROGNOSIS

IMPLICATION NETWORKS
897
1021
938
787
996
992

TETRAD IV (BAYESIAN)
13
13
12
14
13
14

The interactions among the 31 genes extracted from different tools were compared with the
interactions obtained from implication networks and Bayesian networks as concluded in Table 430. It can be seen that the interactions from all the tools were present in implication networks but
most of them did not show up in Bayesian networks.
Table 4-30: Comparison of number of interactions among the 31 genes and the 8 hallmarks identified from
different biomedical tools found in implication networks and Bayesian networks

IMPLICATION NETWORKS

TETRAD IV (BAYESIAN)

MATISSE (8)

100% (8/8)

12.5% (1/8)

PUBMED (5)

100% (5/5)

20% (1/5)

KEGG (7)

100% (7/7)

0% (0/7)

NCI (20)

100% (20/20)

0% (0/20)

STRING(27)

100% (27/27)

3.7% (1/27)

PATHWAY STUDIO (26)

100% (26/26)

3.84% (1/26)

INGENUITY PATHWAY (24)

100% (24/24)

4.16% (1/24)

The interactions from implication networks and Bayesian networks were input in to Prodistin
and the biological processes they are involved are noted down along with the number of
significant processes. It can be seen from Table 4-31 that interactions from Bayesian networks
did not show any biological processes. On the other hand, interaction from implication networks
consisted of many biological processes.
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Table 4-31: Number of Biological Processes identified using Prodistin when interactions from implication
networks and Bayesian networks are given as input.

TRAINING GOOD PROGNOSIS
TRAINING POOR PROGNOSIS
DFCI GOOD PROGNOSIS
DFCI POOR PROGNOSIS
MSK GOOD PROGNOSIS
MSK POOR PROGNOSIS

IMPLICATION NETWORKS
14(3 SIGNIFICANT)
7(2 SIGNIFICANT)
4
2
11 (3 SIGNIFICANT)
11

TETRAD IV (BAYESIAN)
0
0
0
0
0
0

To increase the possibility of biological relevance and to reduce the false discovery rate,
thresholds can be applied on the weight functions of the implication rules. For the results in
Table 4-29, no thresholds were applied and hence there were a large number of interactions. We
applied a threshold on the weight functions (equations 2.17 and 2.18) to reduce the number of
interactions that would remain along with all the interactions from curated databases. The
weights are variables between [0, 1]. The thresholds w1≥0.539474 and w2≥0.333333 made all
the interactions from curated databases remain in the implication networks. For these applied
thresholds, the number of interactions that remain in each of the datasets in Poor and Good
prognosis are summarized in the Table 4-32 below. A few intermediate calculations of threshold
on weights are also shown in the table below.
Table 4-32: Comparison of number of interactions from Poor and Good Prognosis of each dataset in
Implication Networks and Bayesian Networks (using Tetrad IV) with application of thresholds on weights.

TRAINING GOOD PROGNOSIS
TRAINING POOR PROGNOSIS
DFCI GOOD PROGNOSIS
DFCI POOR PROGNOSIS
MSK GOOD PROGNOSIS
MSK POOR PROGNOSIS

No Threshold
on weights
897
1021
938
787
996
992

w1≥0.45
& w2≥0.1
761
856
886
758
949
935
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w1≥0.5 &
w2≥0.1
619
741
851
706
911
877

w1≥0.515
& w2≥0.2
543
678
772
676
849
817

w1≥0.539 &
w2≥0.333
498
563
709
605
752
742

The Figures below show the representation of the values in the Table above for the three datasets
separately. Figure 4-54 shows the variation of the number of gene interactions with threshold on
weights in the Training group. Figure 4-55 shows the variation of the number of gene
interactions with threshold on weights in the DFCI test group. Figure 4-56 shows the variation of
the number of gene interactions with threshold on weights in the MSK test group.
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1000
800

Interactions in
Good prognosis
Training group

600
400

Interactions in
Poor prognosis
Training group

200
0
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on weights
w2≥0.1

w1≥0.5 & w1≥0.515 & w1≥0.539474
w2≥0.1
w2≥0.2
&
w2≥0.333333

Interactions in
Good prognosis
Training group

Figure 4-54: Variation of number of gene interactions with threshold on weights in Training Group. The first
set of data is the number of interactions without any thresholds and the fifth set of data is the number of gene
interactions with the given thresholds which include all the curated interactions. The second, third and fourth
set of data are intermediate set of results to show how the number of gene interactions decrease with an
increase in thresholds.
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Figure 4-55: Variation of number of gene interactions with threshold on weights in DFCI test Group. The
first set of data is the number of interactions without any thresholds and the fifth set of data is the number of
gene interactions with the given thresholds which include all the curated interactions. The second, third and
fourth set of data are intermediate set of results to show how the number of gene interactions decrease with
an increase in thresholds.
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Figure 4-56: Variation of number of gene interactions with threshold on weights in MSK test Group. The first
set of data is the number of interactions without any thresholds and the fifth set of data is the number of gene
interactions with the given thresholds which include all the curated interactions. The second, third and fourth
set of data are intermediate set of results to show how the number of gene interactions decrease with an
increase in thresholds.
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This chapter thus summarizes that the 31 gene signature that has been identified using
implication networks and interactions with hallmarks is a good predictor. It also summarizes that
the model used for generating the 31 gene signature is also very good in detecting more
gene/protein signatures when compared with Bayesian networks.
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Chapter 5

5 Software Implementation
5.1. Introduction
This chapter describes the implementation of the package which was used to perform the
analyses. The package is a combination of C and R where C-code was made to run through the
R-interface. This chapter also describes the different versions of the code available and the
changes between them. It also gives a few screen shots of the implementation of the package and
the configuration of the computer used to run the code.

5.2. Description
All the code was implemented in C. It was compiled at the command prompt to create the .dll
(dynamic linked library) file. After the compilation, the .dll file was loaded in to R. In R, the
code needed 4 filenames as input. Two of these filenames correspond to the files that were given
as input while the other two file names were the names of the output files that were created while
the code executed and the final output was stored. After the execution was over the .dll file that
was loaded initially had to be unloaded to avoid errors in the later executions. The first of the
input files contains the micro array data of patients profile gene expression values of all the
genes along with their gene symbols and the survival time and status at the end of the file. The
second file is the list of the hallmarks that were used. The two output files contain the genes that
interact with all the hallmarks, one file for each of the groups.
There are two versions of the C-codes. Both of them work in the above mentioned manner. But
the main difference between them is the speed of execution and the amount of memory utilized.
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First version of the code generates the entire genome wide interactions and keeps storing them in
the hard disk of the computer while generating. It takes time as there are a lot of memory read
and write operations. The second version of the code generates only the interactions between the
genes and the hallmarks ignoring all the interactions that do not contain at least one of the
hallmarks. This code does not require more memory as it uses linked lists and stores the
interactions in the cache. Thus it is much faster than the first version.
It required around 40 minutes for executing the first version of the package through R. The
second version required around 25 minutes. The codes were executed on a system with the
following configuration: The processor was an Intel® CoreTM2 Duo CPU E8300 @ 2.83GHz.
There was 4.00GB of Memory (RAM) in the system. The C drive was allocated with 455GB of
hard disk space. The version of the R editor used was R-2.7.2 and the C editor used was DevC++ 4.9.9.2.
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5.3. Results & Screenshots

Figure 5-1: Changing the directory to the current directory and compiling the C-code to generate the
required dynamic linked library files to be used for executing code in R

Figure 5-2: C-code for the first version of the package
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Figure 5-3: Main difference between the C-codes shown in the second version of the code

Figure 5-4: Output from R: Red lines are the input code and the next blue lines are the outputs after
execution of the entire package after around 40 minutes
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From the Figure 5-1 shown above, it can be seen that compiling the C-code was done first at the
command prompt and then Figure 5-4 shows the statements to be executed to run the package.
Figures 5-2 and 5-3 show parts of the C-code in the two versions of the package available.

5.4. Summary
This chapter thus shows the screenshots of the C-code. It also describes the differences in the
various versions of the code. The C-code which executes the required process was thus
embedded in to R to form a package which automated the process of finding good prognostic
gene signatures from an entire set of genome wide interactions.
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Chapter 6

6 Conclusions & Prospective Work
6.1. Conclusions
Identifying the critical genes in a network would help in predicting cancer recurrence. Thus a
novel network based methodology was developed which overcame the limitations of feature
selection techniques. It was thus concluded that network-based techniques are capable of finding
accurate and stable signatures when compared to the feature selection methods. They (networkbased techniques) considered the performance of the gene interactions instead of the behavior of
individual genes.
It was also seen from that implication networks are better than the currently used network-based
techniques such as the correlation coefficient based and clustering based coexpression networks,
Bayesian networks, and Artificial neural networks. Implication networks integrate formal logic
and statistics and are thus very efficient. They also overcome the limitations of the currently used
network-based techniques. Comparison of the Bayesian networks was done practically in chapter
4 from which it can be concluded that the prediction logic induced implication networks were
much better in finding more gene/protein connections when compared to the Bayesian networks.
The implication network was another kind of coexpression network which was built using
predication logic. Prognostic signatures were identified from the genome wide coexpression
networks based on the interactions with major cancer hallmarks (E2F, EGF, EGFR, KRAS,
MET, RB1, and TP53). Once the signature was obtained using genome wide implication
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network, it was evaluated prognostically, clinically and structurally to make sure that the
obtained signature was significant.
The Prognostic validation showed that the signature was significant with the help of KM plots,
log-rank p-values, CPE values, and FDR from GSEA. The model was also compared to other
classification methods from Weka. It was found that the Cox model on implication networks was
much better in classifying the instances. Clinical evaluation was performed using multivariate
Cox model with respect to other clinical factors. The signature was highly significant when
compared to other predictors.
Structural validation was done by checking the interactions from implication networks with the
interactions from Bayesian networks generated by Tetrad IV. It was seen from various web
based tools that the implication networks were able to generate many more gene/protein
interactions with biological relevance when compared to Bayesian networks. Weights of the
implication rules were also tuned to increase the possibility of biological relevance and decrease
the false discovery rates. These weights were tuned in such a way that they still include all the
interactions from the curated databases. Thus all the validation methods have concluded that the
signature was good. Thus the implication networks help us in finding the functional clustering
between genes.
Thus it can be concluded that implication networks lead us to identify better down streamed
signatures that can be used in therapeutic conditions.
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6.2. Future Work
A lot of prospective work can be done using this approach.
New signatures are being found using other predictive factors like Smoking status of the patients.
This network generation approach can also be tried with other cancers such as breast cancer,
colon cancer, etc. Cross validation can be performed by using the signatures found in one kind of
cancer to validate using datasets of other kinds of cancers. Different models can be tried with
slight changes in the network generation.
In this thesis, only one set of expression values have been used to build the implication networks.
But implication networks actually have the potential to model dynamic networks with temporal
relevance which can be considered in future clinical trials after surgical resections.
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